WO2004064728A2 - Composes de tetracycline possedant des activites therapeutiques ciblees - Google Patents

Composes de tetracycline possedant des activites therapeutiques ciblees Download PDF

Info

Publication number
WO2004064728A2
WO2004064728A2 PCT/US2004/001036 US2004001036W WO2004064728A2 WO 2004064728 A2 WO2004064728 A2 WO 2004064728A2 US 2004001036 W US2004001036 W US 2004001036W WO 2004064728 A2 WO2004064728 A2 WO 2004064728A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkenyl
alkynyl
aryl
alkoxy
Prior art date
Application number
PCT/US2004/001036
Other languages
English (en)
Other versions
WO2004064728A3 (fr
Inventor
Stuart B. Levy
Michael Draper
Mark L. Nelson
Graham Jones
Original Assignee
Paratek Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals, Inc. filed Critical Paratek Pharmaceuticals, Inc.
Publication of WO2004064728A2 publication Critical patent/WO2004064728A2/fr
Publication of WO2004064728A3 publication Critical patent/WO2004064728A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Inflammation is the body's reaction to injury and infection.
  • Major events involved in inflammatory processes include increased blood supply to the injured or infected area; increased capillary permeability enabled by retraction of endothelial cells; and migration of leukocytes out of the capillaries and into the surrounding tissue (Roitt et al, Immunology, Grower Medical Publishing, New York, 1989).
  • Increased capillary permeability allows larger molecules and cells to cross the endothelium that are not ordinarily capable of doing so, thereby allowing soluble mediators of immunity and leukocytes to reach the injured or infected site.
  • Leukocytes primarily neutrophil polymorphs (also known as polymorphonuclear leukocytes, neutrophils or PMNS) and macrophages, migrate to the injured site by a process known as chemo taxis.
  • tissue damage and complement activation cause the release of chemotactic peptides such as C5a.
  • Complement activation products are also responsible for causing degranulation of phagocytic cells, mast cells and basophils, smooth muscle contraction and increases in vascular permeability (Mulligan et al. 1991 J. Immunol. 148:1479-1485).
  • the traversing of leukocytes from the bloodstream to extravascular sites of inflammation or immune reaction involves a complex but coordinated series of events.
  • signals are generated such as bacterial endotoxins, activated complement fragments or proinflammatory cytokines such as interleukin 1 (IL-1), interleukin 6 (IL-6), and tumor necrosis factor (TNF) which activate leukocytes and/or endothelial cells and cause one or both of these cell types to become adhesive.
  • IL-1 interleukin 1
  • IL-6 interleukin 6
  • TNF tumor necrosis factor
  • Adherent leukocytes travel across the endothelial cell surface, diapedese between endothelial cells and migrate through the subendothelial matrix to the site of inflammation or immune reaction (Harlan et al., Adhesion-Its role in Inflammatory Disease, W. H. Freeman & Co., New York, 1992).
  • leukocyte traversal of vessel walls to extravascular tissue is necessary for host defense against foreign antigens and organisms, leukocyte-endothelial interactions often have deleterious consequences for the host. For example, during the process of adherence and transendothelial migration, leukocytes release oxidants, proteases and cytokines that directly damage endothelium or cause endothelial dysfunction. Once at the extravascular site, emigrated leukocytes further contribute to tissue damage by releasing a variety of inflammatory mediators. Moreover, single leukocytes sticking within the capillary lumen or aggregation of leukocytes within larger vessels are responsible for microvascular occlusion and ischemia.
  • Leukocyte-mediated vascular and tissue injury has been implicated in pathogenesis of a wide variety of clinical disorders such as acute and chronic allograft rejection, vasculitis, rheumatoid and other forms of inflammatory based arthritis, inflammatory skin diseases, adult respiratory distress syndrome, ischemia-reperfusion syndromes such as myocardial infarction, shock, stroke, organ transplantation, crush injury and limb replantation.
  • MS multiple sclerosis
  • inflammatory cells whose products cause tissue injury underlies the pathology of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.
  • Neutrophils, eosinophils, mast cells, lymphocytes and macrophages contribute to the inflammatory response.
  • the invention pertains, at least in part, to a method for treating a disease with a tetracycline compound having a target therapeutic activity.
  • the method includes administering to a subject an effective amount of a tetracycline compound having a target therapeutic activity, such that the disease is treated.
  • R 2 , R 2 , R 4 , and R 4 are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
  • R , R , R , R and R are each hydrogen or a pro-drug moiety
  • R 4 is NR 4' R 4" , alkyl, alkenyl, alkynyl, hydroxyl, halogen, or hydrogen;
  • R 5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;
  • R 6 and R 6 are each independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • R 9 is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic, thionitroso,
  • R 8 , R 8c , R 8d , R 8e , R 8f , R 9a , R 9b , R 9c , R 9d , R 9e , and R ,9f are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
  • R 13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • E is CR 8d
  • W is O, NR 7f , or S;
  • Z is CR 9d R 9e , S, NR 9 or O;
  • Z' is O, S, or NR 9f , and pharmaceutically acceptable salts, esters and enantiomers thereof.
  • the invention also pertains to methods of using tetracyclines of formula (II) and (III).
  • the invention pertains, at least in part, to a method for treating an inflammatory process associated state in a subject, by administering to the subject an effective amount of a tetracycline compound.
  • the tetracycline is substituted at the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 1 la, 12, 12a and/or 13 position.
  • the substituted tetracycline compound is 3, 7, 9 and/or 10 substituted.
  • the invention pertains, at least in part, to methods for treating inflammation process associated states (IP AS) in subjects, by administering to the subject an effective amount of a tetracycline compound, such that the IP AS in the subject is treated.
  • IP AS inflammation process associated states
  • -PAS include, but are not limited to, diabetic complications, arteriosclerosis, atherosclerosis, etc.
  • the invention pertains, at least in part, to a method for treating tissue wounds of a subject.
  • the method includes contacting the subject's wound with an effective amount of a tetracycline compound.
  • the invention also pertains, at least in part, to a method for treating ischemia or stroke in a subject. The method includes administering to a subject an effective amount of a tetracycline compound.
  • the invention also pertains, at least in part, to a method for treating dry eye in a subject.
  • the method includes administering to a subject an effective amount of a tetracycline compound.
  • the invention also includes a method for treating acute lung injury in a subject, comprising administering to said subject an effective amount of a tetracycline compound.
  • the invention pertains to a method for treating a neurological disorder in a subject by administering to the subject an effective amount of a tetracycline compound, such that the neurological disorder in the subject is treated.
  • neurological disorders include, but are not limited to, multiple sclerosis, Parkinson's disease, Huntington's disease, Alzheimer's disease, traumatic brain injury, amylotropic lateral sclerosis, spinal cord trauma, nerve damage, motor neuron disease, etc.
  • the invention pertains to a method for treating cancer in a subject, by administering to the subject an effective amount of a tetracycline compound, such that the cancer is treated.
  • the invention pertains to pharmaceutical compositions which contain a substituted tetracycline compound in combination with a second agent, e.g., a chemotherapeutic agent, neuroprotective agent, and/or an anti-infective agent.
  • a second agent e.g., a chemotherapeutic agent, neuroprotective agent, and/or an anti-infective agent.
  • the invention also pertains, at least in parts, to a packaged composition for the treatment of disease.
  • the packaged composition includes a tetracycline compound having target therapeutic activity and directions for using it for treatment of the disease.
  • the invention also pertains to pharmaceutical compositions comprising the tetracycline compounds disclosed herein, as well as the tetracycline compounds per se.
  • the invention pertains, at least in part, to a method for treating a disease with a tetracycline compound having a target therapeutic activity.
  • the method includes administering to a subject an effective amount of a tetracycline compound having a target therapeutic activity, such that the disease is treated.
  • target therapeutic activity includes activities of tetracycline compounds in a subject that differ from antibacterial and/or antiinfective activity or are in addition to antibacterial and/or antiinfective activity, but result in treatment of a disease as described herein. It should be understood that the tetracycline compound can have antibacterial and/or antiinfective activity, but the treatment of the disease occurs through a different and/or additional target therapeutic activity. Examples of target therapeutic activities include activities that allow for treatment of inflammatory process associated states (IP AS), neurological disorders (e.g., neurodegenerative disorders, neuropsychiatric disorders, etc.), cancer, and other disorders which can be treated with the tetracycline compounds of the invention. Examples of specific TTAs are described in further detail below and in the Examples. Tetracycline compound of the invention may have one or more TTAs.
  • IP AS inflammatory process associated states
  • TTA neurodegenerative disorders, neuropsychiatric disorders, etc.
  • Tetracycline compound of the invention may have one or more TTAs.
  • tetracycline compound does not include minocycline, doxycycline, or tetracycline.
  • the term includes substituted tetracycline compounds or compounds with a similar ring structure to tetracycline.
  • tetracycline compounds include: chlortetracycline, oxytetracycline, demeclocycline, methacycline, sancycline, chelocardin, rolitetracycline, lymecycline, apicycline; clomocycline, guamecycline, meglucycline, mepylcycline, penimepicycline, pipacycline, etamocycline, penimocycline, etc.
  • tetracycline compounds includes substituted tetracycline compounds as defined below, and as described in the specification, in Formula I, II, III, Table 2, Table 3, and/or Table 4.
  • the tetracycline compounds may or may not have antibacterial or antiinfective activity.
  • the tetracycline compound has antiinfective and/or antibacterial activity.
  • the tetracycline compound does not have significant antiinfective or antibacterial therapeutic activity.
  • subject includes animals (e.g., mammals, e.g., cats, dogs, horses, pigs, cows, sheep, rodents, rabbits, squirrels, bears, primates (e.g., chimpanzees, gorillas, and humans)) which are capable of (or currently) suffering from a target disease, such as, but not limited to IP AS, neurological disorders, and cancer.
  • a target disease such as, but not limited to IP AS, neurological disorders, and cancer.
  • effective amount of the tetracycline compound is that amount necessary or sufficient to treat or prevent a target disease of the invention such as, for example, an IP AS, a neurological disorder, or cancer in a subject, e.g. prevent the various morphological and somatic symptoms of the particular disease.
  • the effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular tetracycline compound.
  • the choice of the tetracycline compound can affect what constitutes an "effective amount".
  • One of ordinary skill in the art would be able to study the aforementioned factors and make the determination regarding the effective amount of the tetracycline compound without undue experimentation.
  • the regimen of administration can affect what constitutes an effective amount.
  • the tetracycline compound can be administered to the subject either prior to or after the onset of a disease which is treatable . Further, several divided dosages, as well as staggered dosages, can be administered daily or sequentially, or the dose can be continuously infused, orally administered, administered by inhalation, or can be a bolus injection. Further, the dosages of the tetracycline compound(s) can be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.
  • target disease includes diseases or disorders which may be treated and/or prevented by the administration of a tetracycline compound having target therapeutic activity. Examples of target diseases include, but are not limited to, IP AS, neurological disorders, and cancer.
  • treatment includes therapeutic and/or prophylactic treatment.
  • the treatment includes the diminishment or alleviation of at least one symptom associated or caused by the state, disorder or disease being treated.
  • treatment can be diminishment of one or several symptoms of a disorder or complete eradication of a disorder.
  • the invention pertains to a method for treating a disease (e.g., an IP AS, a neurological disorder, cancer, etc.) in a subject, by administering to said subject an effective amount of a tetracycline compound such that said disease is treated.
  • a disease e.g., an IP AS, a neurological disorder, cancer, etc.
  • the tetracycline compound used in any of the methods is an anti-infective and/or anti-microbial.
  • the tetracycline compound used in any one of the above described methods is not anti-infective and/or anti-microbial.
  • the te ⁇ n "antiinfective" includes antibacterial, antimicrobial, antifungal, antiparasitic, antibiotic, and antiviral activities of the tetracycline compounds.
  • an antiinfective tetracycline compound includes compounds that reduce the ability of a microbe to produce infection in a host or that reduces the ability of a microbe to multiply or remain infective in an environment.
  • Antiinfective tetracycline compounds include those compounds that are static or cidal for microbes, e.g., an antimicrobial compound that inhibits proliferation and/or viability of a microbe.
  • the antiinfective tetracycline compounds include compounds that increase susceptibility of microbes to the tetracycline compound or another agent, e.g., antibiotic, or decrease the infectivity or virulence of a microbe.
  • the antiinfective properties of tetracycline compounds of the invention can be determined by using assays known in the art as well as the assays described herein.
  • the invention pertains to methods for treating diseases with tetracycline compounds having target therapeutic activity, by administering an effective amount of a tetracycline compound having target therapeutic activity in combination with a second agent.
  • the language "in combination with" a second agent or treatment includes co- administration of the tetracycline compound, and with the second agent or treatment, administration of the tetracycline compound first, followed by the second agent or treatment and administration of the second agent or treatment first, followed by the tetracycline compound.
  • the second agent may be any agent which is known in the art to treat, prevent, or reduce the symptoms of a target disease, such as, for example, IP AS, neurological disorder, cancer, etc.
  • the second agent may be any agent of benefit to the patient when administered in combination with the administration of an tetracycline compound. Examples of second agents include chemotherapeutic agents, neuroprotective agents, and antiinfective agents, as described below.
  • the invention pertains to a method for treating an inflammatory process associated state (IP AS) in a subject.
  • the method includes administering to a subject an effective amount of a tetracycline compound of formula I, II, III, Table 2, 3, 4, or otherwise described herein, such that the inflammatory process associated state is treated.
  • IP AS includes states in which inflammation or inflammatory factors (e.g., matrix metalloproteinases (MMPs), nitric oxide (NO), TNF, interleukins, plasma proteins, cellular defense systems, cytokines, lipid metabolites, proteases, toxic radicals, mitochondria, apoptosis, adhesion molecules, etc.) are involved or are present in an area in aberrant amounts, e.g., in amounts which may be advantageous to alter, e.g., to benefit the subject.
  • MMPs matrix metalloproteinases
  • NO nitric oxide
  • TNF interleukins
  • plasma proteins e.g., plasma proteins
  • cellular defense systems e.g., cytokines, lipid metabolites, proteases, toxic radicals, mitochondria, apoptosis, adhesion molecules, etc.
  • cytokines e.g., cytokines, lipid metabolites, proteases, toxic radicals, mitochondria, apoptosis
  • tetracycline compounds may treat inflammatory disorders in subjects by direct inhibition or inl ibition of production of secretions of MMPs, nitric oxide (NO), tumor necrosis factor (TNF), and/or other factors associated with inflammatory processes
  • flammatory disorders include both acute inflammatory disorders, chronic inflammatory disorders, and recurrent inflammatory disorders.
  • Acute inflammatory disorders are generally of relatively short duration, and last for from about a few minutes to about one to two days, although they may last several weeks.
  • the main characteristics of acute inflammatory disorders include increased blood flow, exudation of fluid and plasma proteins (edema) and emigration of leukocytes, such as neutrophils.
  • Chronic inflammatory disorders generally, are of longer duration, e.g., weeks to months to years or even longer, and are associated histologically with the presence of lymphocytes and macrophages and with proliferation of blood vessels and connective tissue.
  • Recurrent inflammatory disorders include disorders which recur after a period of time or which have periodic episodes. Examples of recurrent inflammatory disorders include asthma and multiple sclerosis. Some disorders may fall within one or more categories.
  • Inflammatory disorders are generally characterized by heat, redness, swelling, pain and loss of function.
  • causes of inflammatory disorders include, but are not limited to, microbial infections (e.g., bacterial, viral and fungal infections), physical agents (e.g., burns, radiation, and trauma), chemical agents (e.g., toxins and caustic substances), tissue necrosis and various types of immunologic reactions.
  • NO is believed to be one of a number of reactive products produced in the immune and inflammatory responses to such insults. In particular, elevated levels of NO production common to chronic inflammation are a likely contributor to the non-specific tissue destruction often seen in such conditions.
  • inflammatory disorders include, but are not limited to, osteoarthritis, rheumatoid arthritis, acute and chronic infections (bacterial, viral and fungal); acute and chronic bronchitis, sinusitis, and other respiratory infections, including the common cold; acute and chronic gastroenteritis and colitis; acute and chronic cystitis and urethritis; acute respiratory distress syndrome; cystic fibrosis; acute and chronic dermatitis; acute and chronic conjunctivitis; acute and chronic serositis (pericarditis, peritonitis, synovitis, pleuritis and tendinitis); uremic pericarditis; acute and chronic cholecystis; acute and chronic vaginitis; acute and chronic uveitis; drug reactions; insect bites; burns (thermal, chemical, and electrical); and sunburn.
  • osteoarthritis acute and chronic infections
  • acute and chronic infections bacterial, viral and fungal
  • acute and chronic bronchitis sinusitis, and other respiratory infections, including the
  • NO associated state includes states which involve or are associated with nitric oxide (NO) or inducible nitric oxide synthase (iNOS).
  • NO associated state includes states which are characterized by aberrant amounts of NO and/or iNOS.
  • the NO associated state can be treated by administering tetracycline compounds of the invention, e.g., compounds of formula I, II, III, Table 2, 3, 4, or otherwise described herein, hi certain embodiments, the invention includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a and/or 13 substituted tetracycline compounds, hi other embodiments, the compounds described in U.S. Patents Nos.
  • NO associated states include, but are not limited to, malaria, senescence, diabetes, vascular stroke, neurodegenerative disorders (e.g., Alzheimer's disease, Huntington's disease, amylotropic lateral sclerosis, etc.), cardiac disease (e.g., re-perfusion-associated injury following infarction), juvenile diabetes, inflammatory disorders, osteoarthritis, rheumatoid arthritis, acute and chronic infections (e.g., bacterial, viral and fungal); restenosis; acute and chronic bronchitis, sinusitis, and other respiratory infections, including the common cold; acute and chronic gastroenteritis and colitis; acute and chronic cystitis and urethritis; hepatitis; acute and chronic dermatitis; acute and chronic conjunctivitis; acute and
  • MMPAS matrix metalloproteinase associated states
  • MMPAS include states characterized by aberrant amounts of MMPs or MMP activity.
  • MMP's Matrix metalloproteinases
  • PMN's polymorphonuclear neutrophils
  • macrophages macrophages
  • bone cells epithelium and fibroblasts.
  • MMP's are also expressed during physiological processes such as wound repair, reproduction, tissue growth and remodeling.
  • MMP's matrix metalloproteinase associated states
  • MMP's include, but are not limited to, arteriosclerosis, corneal ulceration, emphysema, osteoarthritis, multiple sclerosis(Liedtke et al, Ann. Neurol 1998, 44:35-46; Chandler et al, J.
  • the tetracycline compounds of the invention do not include those described in U.S. Pat. Nos. 5,459,135; 5,321,017; 5,308,839; 5,258,371; 4,935,412; 4,704,383, 4,666,897, and RE 34,656, incorporated herein by reference in their entirety.
  • the IP AS is diabetes or diabetic complications, e.g., juvenile diabetes, diabetes mellitus, diabetes type I, diabetes type II, or complications associated with anyone of the aforementioned states such as diabetic ulcers.
  • protein glycosylation is not affected by the administration of the tetracycline compounds.
  • the tetracycline compound of the invention is administered in combination with standard diabetic therapies, such as, but not limited to insulin therapy, hi a further embodiment, the tetracycline compounds used to treat diabetes do not include those compounds described in U.S. Patents Nos. 5,929,055; and 5,532,227, incorporated herein by reference in their entirety.
  • the IP AS disorder is a bone mass disorder.
  • Bone mass disorders include disorders where a subjects bones are disorders and states where the formation, repair or remodeling of bone is advantageous.
  • bone mass disorders include osteoporosis (e.g., a decrease in bone strength and density), bone fractures, bone formation associated with surgical procedures (e.g., facial reconstruction), osteogenesis imperfecta (brittle bone disease), hypophosphatasia, Paget's disease, fibrous dysplasia, osteopetrosis, myeloma bone disease, and the depletion of calcium in bone, such as that which is related to primary hyperparathyroidism.
  • Bone mass disorders include all states in which the formation, repair or remodeling of bone is advantageous to the subject as well as all other disorders associated with the bones or skeletal system of a subject which can be treated with the tetracycline compounds of the invention.
  • the tetracycline compounds of the invention used to treat bone mass disorders do not include U.S. Patents Nos. 5,459,135; 5,231,017;
  • the IP AS disorder is acute lung injury.
  • Acute lung injuries include acute respiratory distress syndrome (ARDS), adult respiratory distress syndrome, post-pump syndrome (PPS), and trauma. Trauma includes any injury to living tissue caused by an extrinsic agent or event. Examples of trauma include, but are not limited to, crush injuries, contact with a hard surface, or cutting or other damage to the lungs.
  • the invention also pertains to a method for treating acute lung injury by administering a tetracycline compound (e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a and/or 13 substituted tetracycline compound).
  • a tetracycline compound e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a and/or 13 substituted tetracycline compound.
  • the invention also includes methods for treating chronic lung disorders by administering a tetracycline compound, such as those described herein.
  • the method includes administering to a subject an effective amount of a tetracycline compound such that the chronic lung disorder is treated.
  • chronic lung disorders include, but are not limited, to asthma, cystic fibrosis, and emphysema.
  • the tetracycline compounds of the invention used to treat acute and/or chronic lung disorders do not include those described in U.S. Patents No. 5,977,091; 6,043,231; 5,523,297; and 5,773,430, each of which is hereby incorporated herein by reference in its entirety.
  • the IP AS disorder is ischemia, stroke, or ischemic stroke.
  • the invention also pertains to a method for treating ischemia, stroke, or ischemic stroke by administering an effective amount of a tetracycline compound of the invention (e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a and/or 13 substituted tetracycline compound).
  • a tetracycline compound of the invention e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a and/or 13 substituted tetracycline compound.
  • the tetracycline compounds used to treat ischemia, stroke, or ischemic stroke do not include minocycline, or the compounds described in U.S. Patents No. 6,231,894; 5,773,430; 5,919,775 or 5,789,395, incorporated herein by reference.
  • the IP AS is a skin wound.
  • the method pertains, at least in part, to a method for improving the healing response of the epithelialized tissue (e.g., skin, mucusae) to acute traumatic injury (e.g., cut, bum, scrape, etc.).
  • the method may include using a tetracycline compound of the invention (which may or may not have antibacterial activity) to improve the capacity of the epithelialized tissue to heal acute wounds.
  • the method may increase the rate of collagen accumulation of the healing tissue.
  • the method may also decrease the proteolytic activity in the epthithelialized tissue by decreasing the collagenolytic and/or gelatinolytic activity of MMPs.
  • the tetracycline compound of the invention is administered to the surface of the skin (e.g., topically).
  • the tetracycline compound of the invention used to treat a skin wound does not include those described in U.S. Patent Nos. 5,827,840; 4,704,383; 4,935,412; 5,258,371; 5,308,8391 5,459,135; 5,532,227; or 6,015,804; each of which is incorporated herein by reference in its entirety.
  • the tetracycline compound is substituted at the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a and/or 13 position.
  • the -PAS is an aortic or vascular aneurysm in vascular tissue of a subject (e.g., a subject having or at risk of having an aortic or vascular aneurysm, etc.).
  • the tetracycline compound may by effective to reduce the size of the vascular aneurysm or it may be administered to the subject prior to the onset of the vascular aneurysm such that the aneurysm is prevented.
  • the vascular tissue is an artery, e.g., the aorta, e.g., the abdominal aorta.
  • the tetracycline compound of the invention used to treat the aortic of vascular aneurysm is not described in U.S. Patent Nos. 6,043,225 or 5,834,449, incorporated herein by reference in their entirety.
  • the invention pertains to a method for treating dry eye or other eye disorders in a subject, by administering an effective amount of a tetracycline compound, e.g., a compound of formula I, II, or III, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a and/or 13 substituted tetracycline compound tetracycline compound.
  • the tetracycline compound of the invention used to treat dry eye is not described in U.S. Patent No. 5,308,624 nor 5,698,533, inco ⁇ orated herein by reference in their entirety.
  • a tetracycline compound to treat an -PAS associated disorder can be determined tlirough the use of assays and screening methods known in the art.
  • assays and screening methods known in the art.
  • one art recognized in vitro method for determining the anti-inflammatory effects by the inhibition of nitric oxide and IL-12 synthesis is described in D'Agostino, P. et al. Int Immunopharmacol 2001 Sep;l(9-10):1765-76.
  • the LSMA assay, described in Example 4 may also be used, hi one embodiment of the invention, the substituted tetracycline compounds of the invention inhibit nitric oxide synthesis better than doxycycline, as determined by the assay.
  • the substituted tetracycline compounds of the invention inhibit nitric oxide synthesis 10% or greater, 25% or greater, 30% or greater, 35% or greater, 40% or greater, 45% or greater, 50% or greater, 55% or greater, 60% or greater, 65% or greater, 70% or greater, 75% or greater, 80%) or greater, 85% or greater, 90% or greater, 95% or greater, or 100% or greater better than doxycycline.
  • the IP AS is a state which is associated with an infection such as hepatitis (e.g., viral hepatitis) or sinusitis (e.g., chronic sinusitis).
  • the methods of the invention may comprise administering the tetracycline compound of the invention in combination with an antiinfective agent.
  • the antiinfective agent may be an antiinfective tetracycline or another antiinfective agent known in the art to treat viral, fungal, parasitic or bacterial infections.
  • the compounds of the invention may also be tested in vivo for treatment of -PAS disorders.
  • the substituted tetracycline compounds of the invention may be tested for use in the treatment of -PAS disorders using many known assays and models.
  • the tetracycline compounds of the invention may be tested in vivo for effectiveness in treating aortic aneurysisms (e.g., using the model described in Curci, et al. J. Vase. Surg. 2000; 31: 326-342 or the model described in Example 17); diabetic complications (e.g., using the model described in Ryan et al. Curr. Med. Chem.
  • arteriosclerosis such as atherosclerosis (e.g., using the model described in Bendeck, et al. Arner. J. Path. 2001 :160(3): 1089-1095 or the model described in Example 19); acute respiratory distress syndrome (ARDS, e.g., using the model described in Carney et al. Circulation. 1999 Jul 27;100(4):400-6, or in the assay described in Example 20); septic shock (e.g., using the model described in Antimicrob Agents Chemother. 1997 Jan;41(l):l 17-21, Shapira et ⁇ t * . Infect Immun.
  • atherosclerosis e.g., using the model described in Bendeck, et al. Arner. J. Path. 2001 :160(3): 1089-1095 or the model described in Example 19
  • ARDS acute respiratory distress syndrome
  • septic shock e.g., using the model described in Antimicrob Agents Chemother. 1997 Jan;41(l):l 17-21, Shapira
  • the inflammatory process associated state is a mitochondrial associated state.
  • mitochondrial associated states includes states which can be treated by the modulation or modification of mitochondrial physiology, modulation of free radical production, energy state (e.g., of the subject or of the subject's mitochondria), modulation or modification of permeability transition, and/or modification of mitochondrial pathophysiology, e.g., pathophysiology related to calcium trafficking and storage under mitochondrial control.
  • the inflammation associated state is associated with activation of immune related cells types. Examples of immune related cell types include, but are not limited to, macrophage cells, microglial cells, and leukocytes.
  • the activation of immune related cell types may involve the production of inflammatory factors , such as, for example, cytokines, MMPs, ROS, and NO.
  • the activation of immune related cell types may also involve the adhesion or migration of cells.
  • the invention pertains, at least in part, to the modulation of the activation of immune related cell types, as well as modulation of the adhesion or migration of cells.
  • the tetracycline compounds of the invention are found to be effective for the treatment for at least one of the above mentioned disorders using one of the listed models or assays or by using other techniques known in the art to determine efficacy.
  • the invention pertains to methods for treating neurological disorders using tetracycline compounds having target activity.
  • the method includes administering to a subject an effective amount of a tetracycline compound, such that the neurological disorder is treated.
  • neurological disorders include both neuropsychiatric and neurodegenerative disorders, but are not limited to, such as Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, senile dementia, Huntington's disease, Gilles de la Tourette's syndrome, multiple sclerosis, amylotropic lateral sclerosis (ALS), progressive supranuclear palsy, epilepsy, and Creutzfeldt- Jakob disease; autonomic function disorders such as hypertension and sleep disorders, and neuropsychiatric disorders, such as depression, schizophrenia, schizoaffective disorder, Korsakoff s psychosis, mania, anxiety disorders, or phobic disorders; learning or memory disorders, e.g., amnesia or age-related memory loss, attention deficit disorder, dysthymic disorder, major depressive disorder, mania, obsessive-compulsive disorder, psychoactive substance use disorders, anxiety, phobias, panic disorder, as well as bipolar affective
  • tetracycline compounds of the invention used to treat neurological disorders include substituted tetracycline compounds which may be further substituted at the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a and/or 13 position.
  • neuroprotective agents that can be administered in combination with the tetracycline compounds of the invention to treat neurological disorders include, but are not limited to, compounds that remove protein build up (e.g., geldanamycin), anti-inflammatory agents (e.g., glucocorticoids, non-steroidal anti-inflammatory drugs (e.g., ibuprofin, aspirin, etc.), omega-3 fatty acids (e.g., EPA, DHA, etc.), minocycline, dexanabionol, etc.), compounds that increase energy available to cells (e.g., creatine, creatine phosphate, dichloroacetate, nicotinamide, riboflavin, camitine, etc.), anti- oxidants (e.g., plant extracts (e.g., gingko biloba), co-enzyme Q-10, vitamin E (alpha- tocopherol), vitamin C (ascorbic acid), vitamin A (beta-carotene), selenium, lip
  • NBD A N-methyl-D-aspartate
  • opiod antagonists e.g., CDP-choline, etc.
  • calcium and sodium channel blockers prednisone, etc.
  • Examples of in vitro models which can be used to identify tetracyclines which have neuroprotection activity include the NSNA described in Example 6.
  • Other assays which can be used include those described in Shukla C et al, Neuropathol Appl
  • the tetracycline compounds of the invention are found to have neuroprotective activity as measured by the NSNCL assay.
  • NSNCL assay Another example of an in vitro model is the NE Assay (NMDA exposure assay) which measures the protection of cultured cortical neurons from excitotoxic injury induced by NMDA exposure by tetracycline compounds. This assay is described in Example 5 and a similar model is described in Tikka, TM et al. J Immunol. 2001 Jun 15;166(12):7527-33.
  • the tetracycline compounds of the invention are found to protect cultured cortical neurons as determined by the NE assay.
  • the ability of tetracycline compounds to protect dopaminergic cells can be determined by using the assay described in Example 7 (In vitro Parkinson's Disease Assay), or in Le, W et al. J Neurosci. 2001 Nov l;21(21):8447-55. This assay can be used to determine the ability of the tetracycline compounds to treat Parkinson's disease. Microglial activation and oxidative stress are components of the pathology of Parkinson's disease (PD).
  • PD Parkinson's disease
  • the neuroprotective qualities of tetracycline compounds can be assessed using an in vitro model of nigral injury, hi this model, lipopolysaccharide- induced microglial activation leads to injury of a dopaminergic cell line (MES 23.5 cells) and dopaminergic neurons in primary mesencephalic cell cultures.
  • the tetracycline compounds of the invention are able to protect dopaminergic cells as tested in the in vitro Parkinson's Disease Assay.
  • the tetracycline compounds of the invention may also be tested in in vitro models for inhibition of cytochrome C release (CCR Assay). Examples of such assays are described in Example 8 and in the literature (e.g., Zhu S. et al. Nature. 2002 May 2;417(6884):74-8). hi a further embodiment, the tetracycline compounds of the invention are determined to inhibit the cytochrome C release as measured by the CCR Assay.
  • Other in vitro assays that can be used to test the efficacy of the tetracycline compounds of the invention to treat particular states include the Motor Neuron Disease Assay described in Example 25 or the assay described in Tikka et al. Brain. 2002:125(4):722-731.
  • the tetracycline compounds can also be tested for neuroprotective and ability to treat neurological diseases in vivo.
  • the ability of the tetracycline compounds to treat neurological disorders can be determined using in vivo models for amylotropic lateral sclerosis (e.g., Example 9 or as described in Zhu S et al. Nature. 2002 May 2; 417 (6884):74-8), Huntington's disease (e.g., Example 10, or as described in Chen, M. et al. Nat Med. 2000 Jul;6(7):797-801); Parkinson's disease (e.g., Example 11, or as described in Wu, D.C. et al J Neurosci. 2002 Mar 1;22(5):1763-71; or Du, Y.
  • amylotropic lateral sclerosis e.g., Example 9 or as described in Zhu S et al. Nature. 2002 May 2; 417 (6884):74-8
  • Huntington's disease e.g., Example 10, or as described
  • the invention pertains to tetracycline compounds of the invention which are found to be effective for treatment in at least one of the above referenced models.
  • the tetracycline compound for the treatment of the neurological disorder is not one described in U. S . 6,277,393 ; WO 02/20022; WO
  • the tetracycline compound is not a compound described in US 20010014670, when the neurological disorder is Alzheimer's disease, hi a further embodiment, the tetracycline compound is not a compound described in US 20020022608 Al, when the neurological disorder is multiple sclerosis. The contents of each of these references are hereby inco ⁇ orated herein by reference. In another embodiment, the tetracycline compound is not minocycline.
  • the tetracycline compounds of the invention are found to be effective for the treatment for at least one of the above mentioned disorders using one of the listed models or assays or by using other techniques known in the art to determine efficacy.
  • the target disease is cancer.
  • the invention pertains, at least in part, to methods for treating cancer in a subject by administering to the subject an effective amount of a tetracycline compound, such that the cancer in said subject is treated.
  • carcinomas e.g., adenocarcinomas
  • sarcomas are carcinomas derived from glandular tissue or in which the tumor cells form recognizable glandular stractures.
  • Sarcomas broadly include tumors whose cells are embedded in a fibrillar or homogeneous substance like embryonic connective tissue.
  • carcinomas which may be treated using the methods of the invention include, but are not limited to, carcinomas of the prostate, breast, ovary, testis, lung, colon, and breast.
  • the methods of the invention are not limited to the treatment of these tumor types, but extend to any solid tumor derived from any organ system.
  • treatable cancers include, but are not limited to, colon cancer, bladder cancer, breast cancer, melanoma, ovarian carcinoma, prostatic carcinoma, lung cancer, and a variety of other cancers as well.
  • the methods of the invention also cause the inhibition of cancer growth in adenocarcinomas, such as, for example, those of the prostate, breast, kidney, ovary, testes, and colon.
  • the invention pertains to a method for treating a subject suffering or at risk of suffering from cancer, by administering an effective amount of a tetracycline compound, such that inhibition cancer cell growth occurs, i.e., cellular proliferation, invasiveness, metastasis, or tumor incidence is decreased, slowed, or stopped.
  • the inhibition may result from i-nbibition of an inflammatory process, down- regulation of an inflammatory process, some other mechanism, or a combination of mechanisms.
  • the tetracycline compounds may be useful for preventing cancer recurrence, for example, to treat residual cancer following surgical resection or radiation therapy.
  • the compounds of the invention may be administered in combination with standard cancer therapy, such as, but not limited to, chemotherapeutic agents and radiation therapy.
  • chemotherapeutic agent is intended to include chemical reagents which inhibit the growth of proliferating cells or tissues wherein the growth of such cells or tissues is undesirable or otherwise treat at least one resulting symptom of such a growth.
  • Chemotherapeutic agents are well known in the art (see e.g., Gilman A.G., et al, The Pharmacological Basis of Therapeutics, 8th Ed., Sec 12:1202-1263 (1990)), and are typically used to treat neoplastic diseases.
  • chemotherapeutic agents include: bleomycin, docetaxel (Taxotere), doxorabicin, edafrexate, etoposide, finasteride (Proscar), flutamide (Eulexin), gemcitabine (Gemzar), goserelin acetate (Zoladex), granisetron (Kytril), irinotecan (Campto/Camptosar), ondansetron (Zofran), paclitaxel (Taxol), pegaspargase (Oncaspar), piloca ⁇ ine hydrochloride (Salagen), porfimer sodium (Photofrin), interleukin-2 (Proleukin), rituximab (Rituxan), topotecan (Hycamtin), trastuzumab (Herceptin), tretinoin (Retin-A), Triapine, vincristine, and vinorelbine tartrate (Navelbine).
  • chemotherapeutic agents include alkylating drugs such as Nitrogen Mustards (e.g., Mechlorethamine (HN 2 ), Cyclophosphamide, Ifosfamide, Melphalan (L-sarcolysin), Chlorambucil, etc.); ethylenimines, methylmelamines (e.g., Hexamethylmelamine, Thiotepa, etc.); Alkyl Sulfonates (e.g., Busulfan, etc.), Nitrosoureas (e.g., Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl- CCNU), Streptozocin (streptozotocin), etc.), triazenes (e.g., Decarbazine (DTIC; dimethyltriazenoimi-dazolecarboxamide)), Alkylators (e.g., cis- diamminedichloroplatinum II (CDDP)), etc.
  • chemotherapeutic agents include antimetabolites such as folic acid analogs (e.g., Methotrexate (amethopterin)); pyrimidine analogs (e.g., fluorouracil ('5-fluorouracil; 5-FU); floxuridine (fluorode-oxyuridine); FUdr; Cytarabine (cyosine arabinoside), etc.); purine analogs (e.g., Mercaptopurine (6-mercaptopurine; 6-MP); Thioguanine (6-thioguanine; TG); and Pentostatin (2'-deoxycoformycin)), etc.
  • chemotherapeutic agents also include vinca alkaloids (e.g.,
  • Vinblastin VLB and Vincristine
  • topoisomerase inhibitors e.g., Etoposide, Teniposide, Camptothecin, Topotecan, 9-amino-campotothecin CPT-11, etc.
  • antibiotics e.g., Dactinomycin (actinomycin D), adriamycin, daunorubicin, doxorabicin, bleomycin, plicamycin (mithramycin), mitomycin (mitomycin C), Taxol, Taxotere, etc.
  • enzymes e.g., L-Asparaginase
  • biological response modifiers e.g., interferon-; interleukin 2, etc.
  • chemotherapeutic agents include cis-diaminedichloroplatinum II (CDDP); Carboplatin; Anthracendione (e.g., Mitoxantrone); Hydroxyurea; Procarbazine (N-methylhydrazine); and adrenocortical suppressants (e.g., Mitotane, aminoglutethimide, etc.).
  • CDDP cis-diaminedichloroplatinum II
  • Carboplatin Carboplatin
  • Anthracendione e.g., Mitoxantrone
  • Hydroxyurea e.g., Procarbazine (N-methylhydrazine)
  • Procarbazine N-methylhydrazine
  • adrenocortical suppressants e.g., Mitotane, aminoglutethimide, etc.
  • chemotherapeutic agents include adrenocorticosteroids (e.g., Prednisone); progestins (e.g., Hydroxyprogesterone caproate,; Medroxyprogesterone acetate, Megestrol acetate, etc.); estrogens (e.g., diethylstilbestrol; ethenyl estradiol, etc.); antiestrogens (e.g. Tamoxifen, etc.); androgens (e.g., testosterone propionate,
  • adrenocorticosteroids e.g., Prednisone
  • progestins e.g., Hydroxyprogesterone caproate,; Medroxyprogesterone acetate, Megestrol acetate, etc.
  • estrogens e.g., diethylstilbestrol; ethenyl estradiol, etc.
  • antiestrogens e.g. Tamoxifen, etc.
  • Fluoxymesterone, etc. antiandrogens (e.g., Flutamide); and gonadotropin-releasing hormone analogs (e.g., Leuprolide).
  • antiandrogens e.g., Flutamide
  • gonadotropin-releasing hormone analogs e.g., Leuprolide
  • radiation therapy includes the application of a genetically and somatically safe level of x-rays, both localized and non-localized, to a subject to inhibit, reduce, or prevent symptoms or conditions associated with cancer or other undesirable cell growth.
  • x-rays includes clinically acceptable radioactive elements and isotopes thereof, as well as the radioactive emissions therefrom. Examples of the types of emissions include alpha rays, beta rays including hard betas, high energy electrons, and gamma rays.
  • Radiation therapy is well known in the art (see e.g., Fishbach, F., Laboratory Diagnostic Tests, 3rd Ed., Ch. 10: 581-644 (1988)), and is typically used to treat neoplastic diseases.
  • the tetracycline compounds for treating cancer do not include, for example the tetracycline compounds described in U.S. Patent Nos. 6,100,248; 5,843,925; 5,837,696; 5,668,122; WO 98/31224; US 20020045603; WO 99/49871; WO 01/87823; WO 00/28983; U.S. 5,574,026; , inco ⁇ orated herein by reference in their entirety.
  • the tetracycline compound of the invention is administered in a dosage effective to inhibit the enzymatic activity of at least one matrix metalloproteinase, such as collagenase or gelatinase (e.g., gelatinase A or gelatinase B) associated with cancerous tumors (e.g. , neoplasms) in the subject, e.g. , a mammal.
  • matrix metalloproteinase such as collagenase or gelatinase (e.g., gelatinase A or gelatinase B) associated with cancerous tumors (e.g. , neoplasms) in the subject, e.g. , a mammal.
  • the tetracycline compounds of the invention are found to modulate angiogenesis as determined by the Rabbit Cornea Angiogenesis Model described in Example 14.
  • Other in vitro assays which can be used to determine the ability of the test tetracycline compounds of the invention's ability to inhibit angiogenesis include those described in Tamargo R.J. et al. Cancer Res. 1991 Jan
  • Another in vitro assay which can be used to determine the ability of a test compound to modulate undesired cell growth include, for example, the In vitro Cancer Assay, described in Example 15.
  • the tetracycline compounds of the invention are found to inhibit or decrease tube formation as determined by the In vitro Cancer Assay.
  • the tetracycline compounds of the invention are found to impair or prevent de novo tumor growth.
  • the ability of the tetracycline compounds of the invention to impair or prevent de novo tumor growth can be determined, for example, by the assay described in Example 16, or by using assays described in the literature, such as, for example, Parangi S. et al. PNAS 1996 Mar 5;93(5):2002-7 or Seftor RE et ⁇ /. din Exp Metastasis. 1998 A ⁇ r;16(3):217-25.
  • substituted tetracycline compound includes tetracycline compounds with one or more additional substituents, e.g., at the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a or 13 position or at any other position which allows the substituted tetracycline compound of the invention to perform its intended function, e.g., treat target diseases such as IP AS, neurological disorders, and cancer.
  • substituted tetracycline compounds include compounds described in U.S. Patents Nos. 6,165,999; 5,834,450; 5,886,175; 5,567,697; 5,567,692; 5,530,557; 5,512,553; 5,430,162, each of which is inco ⁇ orated herein by reference in its entirety.
  • Other examples of substituted tetracycline compounds include those described in, for example, WO 03/079984, WO 03/075857, WO 03/057169, WO 02/072545, WO
  • R 2 , R 2 , R 4' , and R 4" are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
  • R 2 , R 3 , R 10 , R ⁇ and R 12 are each hydrogen or a pro-drug moiety
  • R 4 is NR 4 R 4 , alkyl, alkenyl, alkynyl, hydroxyl, halogen, or hydrogen;
  • R 5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;
  • R 6 and R 6 are each independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • R >9 y f ⁇ a . re each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
  • R 13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • E is CR ) 8 ⁇ d Q R ⁇ >8e , S, NR 8 a b D or O;
  • E' is O, NR S H f, or S
  • W is CR .7 / d ⁇ -Rr»7 / e e , S, NR 7 / b D or O W' is O, NR 7f , or S;
  • Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • Z is CR 9d R e , S, NR 9b or O;
  • Z' is O, S, or NR 9f , and pharmaceutically acceptable salts, esters and enantiomers thereof.
  • R 2 , R 2' , R 8 , R 10 , R 11 , and R 12 are each hydrogen, X is
  • R 4 is NR 4 R 4" , wherein R 4' and R 4" are each methyl, hi another embodiment, R 4 is hydrogen.
  • R 9 may also be hydrogen.
  • the substituted tetracycline compounds used in the methods and compositions of the invention are substituted sancycline compounds, e.g., with substitution at the, for example, 2, 5, 6, 7,8, 9, 10, 11, 1 la, 12, 12a position and/or, in the case of methacycline, 13.
  • R , R , R 10 , R 11 , and R 12 are each hydrogen or a prodrug moiety;
  • R 4 and R 4 are each alkyl (e.g., lower alkyl, e.g., methyl);
  • X is CR 6 R 6' ; and
  • R 2 , R 5 , R 6 , R 6' , and R 8 are each, generally, hydrogen.
  • the substituted tetracycline compound is a substituted tetracycline (e.g., generally, wherein R 4 is NR 4 R 4" , R 4' and R 4 are methyl, R 5 is hydrogen and X is CR 6 R 6 , wherein R 6 is methyl and R 6 is hydroxy); substituted doxycycline (e.g., wherein R 4 is NR 4 R 4 , R 4 and R 4 are methyl, R 5 is hydroxyl and X is CR 6 R 6 , wherein R 6 is methyl and R 6 is hydrogen); substituted minocycline (e.g., wherein R 4 is NR 4 R 4" , R 4' and R 4" are methyl; R 5 is hydrogen and X is CR 6 R 6 wherein R 6 and R 6' are hydrogen atoms and R 7 is dimethylamino) or substituted sancycline
  • R 7 is substituted or unsubstituted aryl.
  • the aryl group may be substituted with one or more substituents, such as, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl.
  • R 7 also may be a substituted or unsubstituted heterocycle.
  • heterocycles include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, pyrimidine, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxophenyl, quinoline, isoquinoline, naphthridine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine, mo ⁇ holine, piperazine, piperidine, etc.
  • substituents for the heterocyclic R 7 group include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio
  • heterocyclic R group is substituted with an amino group or another functional group.
  • R 7 is substituted or unsubstituted alkenyl or, alternatively, substituted or unsubstituted alkynyl.
  • R 7 alkynyl group examples include, but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio
  • R 7 is substituted or unsubstituted alkyl.
  • substituents for the alkyl R 7 group include, but are not limited to, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino
  • R 7 is substituted with aryl groups, carbonyl groups, and amino groups (-NH groups, alkylamino groups, dialkylamino groups, alkenylamino groups, dialkenyl amino groups, arylamino groups, etc.).
  • R 7c is hydrogen, and W and W' are each oxygen.
  • R 7 is acyl, amino, oximyl, or a dimeric moiety.
  • substituents such as, but not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ure
  • substituents such as, but not limited to,
  • R 7 is hydrogen or dimethylamino.
  • R 9 is amino (e.g., -NH , alkylamino, dialkylmino, alkenylamino, etc.). hi another embodiment, R 9 is substituted or unsubstituted alkyl.
  • substituents for the alkyl group include, but are not limited to, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thio
  • the alkyl R 9 group is substituted with an amino or amido group.
  • the amino group may, for example, be further substituted with an alkylamino group or other group described above.
  • R 9 is substituted or unsubstituted aryl.
  • the aryl group may be heterocyclic (pyrcole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, pyrimidine, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxophenyl, quinoline, isoquinoline, naphthridine, indole, benzofuran, purine, benzofuran, or deazapurine) or carbocyclic (e.g., phenyl, etc.).
  • heterocyclic pyrcole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, is
  • substituents for aryl R 9 groups include, but are not limited to, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, hydroxy
  • R 9 is substituted or unsubstituted alkynyl.
  • R 9c include hydrogen.
  • Z' and Z include oxygen and nitrogen, hi another embodiment, R 9c is hydrogen, Z' and Z are each oxygen.
  • R 9c is hydrogen, Z' is oxygen and Z is nitrogen.
  • R 9 is substituted or unsubstituted alkyl or alkylamino.
  • substituents for R 9 include but are not limited to alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino
  • R 9 maybe substituted with alkyl, e.g., R 9 may be alkylaminoalkyl.
  • R 7 may be substituted or unsubstituted alkyl, alkynyl, or a heterocycle. R also maybe substituted with amino.
  • substituents for R 13 include, but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, hydroxy
  • compounds of the invention include tetracycline compounds wherein R 2 is alkyl (e.g., 2-alkyl doxycycline compounds).
  • R 2 is alkyl
  • Other compounds also include compounds wherein R 5 is an ester or prodrug moiety.
  • Other compounds of the invention include compounds wherein R 10 is alkyl.
  • substituted tetracycline compounds of the invention include compounds of Tables 2, 3, and 4, the compounds shown below, and pharmaceutically acceptable esters, prodrugs and salts thereof.
  • substituted tetracycline compounds are of formula
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, or halogen, optionally linked to R 2 to form a ring;
  • R 2 is hydrogen, alkyl, halogen, alkenyl, alkynyl, aryl, hydroxyl, thiol, cyano, nitro, acyl, formyl, alkoxy, amino, alkylamino, heterocyclic, or absent, optionally linked to R 1 to form a ring;
  • R 2 , R 2 , R 4 , and R 4 are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
  • R , 10 , n Ril and R , 12 are each hydrogen, alkyl, aryl, benzyl, arylalkyl, or a pro-drug moiety;
  • R 4 and R 4' are each independently NR 4a R 4 , alkyl, alkenyl, alkynyl, hydroxyl, halogen, or hydrogen;
  • R 5 and R 5' are each independently hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;
  • R 6 and R 6' are each independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • R 9 is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic,
  • R 7a , R 7b , R 7c , R 7d , R 7e , R 7f , R 8a , R 8b , R 8c , R 8d , R 8e , R 8f , R 9a , R 9b , R 9c , R d , R 9e , and R 9f are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
  • R 13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • E is CR 8d R 8e , S, NR 8b or O;
  • E' is O, NR 8f , or S;
  • Q is a double bond when R 2 is absent, Q is a single bond when R 2 is hydrogen, alkyl, halogen, hydroxyl, thiol, alkenyl, alkynyl, aryl, acyl, formyl, alkoxy, amino, alkylamino, or heterocyclic;
  • W is CR 7d R 7e , S, NR 7b or O; W' is O, NR 7f , or S;
  • Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • Z is CR 9d R e , S, NR 9b or O;
  • Z' is O, S, or NR 9f , and pharmaceutically acceptable salts, esters, prodrugs, and enantiomers thereof.
  • the substituted tetracycline compounds are of the formula (in):
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, amido, alkylamino, amino, arylamino, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxy, alkoxycarbonyl, alkylcarbonyloxy, alkyloxycarbonyloxy, arylcarbonyloxy, aryloxy, thiol, alkylthio, arylthio, alkenyl, heterocyclic, hydroxy, or halogen;
  • R >2' , R , R ,4a , and R ,4b are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
  • R , R , R and R are each independently hydrogen, alkyl, aryl, benzyl, arylalkyl, or a pro-drug moiety;
  • R 4 and R 4 are each independently NR 4a R 4b , alkyl, alkenyl, alkynyl, hydroxyl, halogen, or hydrogen;
  • R 5 and R 5 are each independently hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy; ⁇ r
  • R and R are each independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • R 7 is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic, thionitroso, or
  • R 9 is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic, thionitroso, R 7a , R 7 " 3 , R 7c , R 7d , R 7e , R 7f , R 8a , R 8b , R 8c , R 8d , R 8e , R 8f , R 9a , R 9b , R 9c , R 9d , R 9e , and
  • R are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;
  • R 13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;
  • E is CR 8d R 8e , S, NR 8 or O;
  • E' is O, NR 8f , or S;
  • W is CR 7d R 7e , S, NR 7b or O;
  • W' is O, NR 7f , or S;
  • Z' is O, S, or NR , and pharmaceutically acceptable salts, esters and enantiomers thereof.
  • the invention pertains to using tetracycline compounds of formula II or III, wherein R 2 , R 3 , R 10 , R 11 , and R 12 are each hydrogen or a prodrug moiety; R 4 is NR 4a R 4 ; R 4a and R 4 are each alkyl; X is CR 6 R 6' ; and R 2" , R 4' , R 5 , R 5' , R 6 , and R are each hydrogen.
  • the invention pertains to using tetracycline compounds of formula II or III, wherein R 4 is NR 4a R 4 ; R 4a and R 4b are each alkyl; R 5 and R 5' are hydrogen and X is CR 6 R 6 , wherein R 6 is methyl and R 6 is hydroxy.
  • the invention pertains to using tetracycline compounds of formula II or III, wherein R 4 is NR 4a R 4b ; R 4a and R 4 are each alkyl (e.g., methyl); R 5 is hydroxyl; X is CR 6 R 6' ; R 6 is methyl; and R 5' and R 6' are hydrogen.
  • the invention pertains to using tetracycline compounds of fonnula II or III, wherein R 4 is NR 4a R 4b ; R 4a and R 4 are each alkyl (e.g., methyl); X is CR 6 R 6 ; R 5 , R 5 , R 6 and R 6 are hydrogen atoms and R 7 is dimethylamino.
  • the invention pertains to methods of using tetracycline compounds of formula II and or III, wherein R 1 is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), hydroxy, thiol, amino, cyano, acyl, alkoxy, carboxyl, amido, alkyl, alkenyl, alkynyl, aryl, heterocyclic, alkylamino, or any other substituent which allows the tetracycline compound to perform its intended function.
  • halogen e.g., fluorine, chlorine, bromine, iodine, etc.
  • the invention pertains to tetracycline compounds of formula II, wherein Q is a single bond.
  • Q is a single bond
  • the invention pertains to tetracycline compounds wherein R 2 is hydrogen, halogen, cyano, alkyl, hydroxy, alkoxy, or any other substituent which allows the compounds of the invention to perform their intended function.
  • the invention pertains to tetracycline compounds of formula II, wherein Q is a double bond.
  • R 1 invention pertains to tetracycline compounds wherein R and R are linked to form a ring.
  • R and R are linked to form an epoxide, a lactam, a lactone, a carboxylic ring, a heterocyclic ring, or other ring structure.
  • R 1 and R 2 are linked to form a 3, 4, 5, 6, 7, 8, or 9 membered ring.
  • R , R , R , and R are each independently hydrogen, alkyl, acyl, aryl, or arylalkyl.
  • Other R , R , R , and R moieties are described in U.S.S.N. 10/619,653, inco ⁇ orated herein by reference in its entirety.
  • Other examples of R 2' and R 2" moieties are described in U.S. Published Application 20040002481.
  • tetracycline compounds of the invention are shown in Tables 2, 3, and 4.
  • the substituted tetracycline compounds of the invention have antibacterial activity against gram + and/or gram - bacteria.
  • the tetracycline compounds of the invention do not have antibacterial activity against gram + and/or gram - bacteria.
  • the results of an antibacterial MIC assay (as described in Example 3) is shown in Table 3 for both gram + and gram - bacteria .
  • compounds with MIC less than or equal to 4 ⁇ g/ml are indicated with ** and compounds with an MIC of greater than 4 ⁇ g/ml are indicated with *.
  • compounds with MIC of less than about 50 ⁇ g/ml, less than about 40 ⁇ g/ml, less than about 30 ⁇ g/ml, less than about 25 ⁇ g/ml, less than about 20 ⁇ g/ml, less than about 15 ⁇ g/ml, less than about 14 ⁇ g/ml, less than about 13 ⁇ g/ml, less than about 12 ⁇ g/ml, less than about 11 ⁇ g/ml, less than about 10 ⁇ g/ml, less than about 9 ⁇ g/ml, less than about 8 ⁇ g/ml, less than about 6 ⁇ g/ml, less than about 5 ⁇ g/ml, less than about 4 ⁇ g/ml, less than about 3 ⁇ g/ml, less than about 2 ⁇ g/ml, less than about 1 ⁇ g/ml, or less than about 0.5 ⁇ g/ml for gram + and/or gram - bacteria are considered to have anti-bacterial activity.
  • the tetracycline compound of the invention may retain antibiotic, antibacterial, or antimicrobial activity, it may have decreased antibiotic, antibacterial, or antimicrobial activity, or, it may have little to no antibiotic, antibacterial or antimicrobial activity.
  • the substituted tetracycline compound is substituted at the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 1 la, 12, 12a and/or 13 position, hi certain embodiments, the tetracycline compounds of the invention are 7 and/or 9 substituted, e.g., 7 and/or 9-substituted tetracycline compounds (e.g., compounds wherein R 7 and/or R 9 are not both hydrogen).
  • the tetracycline compounds of the invention are 7 and/or 9 substituted sancycline compounds.
  • Other examples of tetracycline compounds which may be used in the methods of the invention include those shown in Tables 2, 3, or 4 or otherwise described herein or inco ⁇ orated by reference.
  • the substituted tetracycline compounds of the invention can be synthesized using the methods described in Example 1, in the following schemes and or by using art recognized techniques. All novel substituted tetracycline compounds described herein are included in the invention as compounds.
  • 9- and 7- substituted tetracyclines can be synthesized by the method shown in Scheme 1.
  • 9- and 7-substituted tetracycline compounds can be synthesized by treating a tetracycline compound (e.g., doxycycline, 1 A), with sulfuric acid and sodium nitrate.
  • the resulting product is a mixture of the 7-nitro and 9-nitro isomers (IB and 1C, respectively).
  • the 7-nitro (IB) and 9- nitro (1C) derivatives are treated by hydrogenation using hydrogen gas and a platinum catalyst to yield amines ID and IE.
  • the isomers are separated at this time by conventional methods.
  • the 7- or 9-amino tetracycline compound (IE and IF, respectively) is treated with HONO, to yield the diazonium salt (1G and IH).
  • the salt (1G and IH) is treated with an appropriate reactive reagent to yield the desired compound(e.g., in Scheme 1, 7-cyclopent-l-enyl doxycycline (IH) and 9-cyclopent-l - enyl doxycycline (II)).
  • tetracycline compounds of the invention wherein R is a carbamate or a urea derivative can be synthesized using the following protocol.
  • Sancycline (2A) is treated with NaNO under acidic conditions forming 7-nitro sancycline (2B) in a mixture of positional isomers.
  • 7-nitrosancycline (2B) is then treated with H 2 gas and a platinum catalyst to form the 7-amino sancycline derivative (2C).
  • isocyanate (2D) is reacted with the 7-amino sancycline derivative (2C).
  • carbamate (2G) the appropriate acid chloride ester (2F) is reacted with 2C.
  • tetracycline compounds of the invention wherein R 7 is a heterocyclic (i.e. thiazole) substituted amino group can be synthesized using the above protocol.
  • 7-amino sancycline (3A) is reacted with Fmoc-isothiocyanate (3B) to produce the protected thiourea (3C).
  • the protected thiourea (3C) is then deprotected yielding the active sancycline thiourea (3D) compound.
  • the sancycline thiourea (3D) is reacted with an ⁇ -haloketone (3E) to produce a thiazole substituted 7-amino sancycline (3F).
  • 7- alkenyl tetracycline compounds such as 7-alkynyl sancycline (4A) and 7- alkenyl sancycline (4B), can be hydrogenated to form 7-alkyl substituted tetracycline compounds (e.g., 7-alkyl sancycline, 4C).
  • Scheme 4 depicts the selective hydrogenation of the 7- position double or triple bond, in saturated methanol and hydrochloric acid solution with a palladium/carbon catalyst under pressure, to yield the product.
  • a general synthetic scheme for synthesizing 7-position aryl derivatives is shown.
  • a Suzuki coupling of an aryl boronic acid with an iodosancycline compound is shown.
  • An iodo sancycline compound (5B) can be synthesized from sancycline by treatmg sancycline (5 A) with at least one equivalent N-iodosuccinimide (NIS) under acidic conditions. The reaction is quenched, and the resulting 7-iodo sancycline (5B) can then be purified using standard techniques known in the art.
  • 7-iodo sancycline (5B) is treated with an aqueous base (e.g., Na 2 CO 3 ) and an appropriate boronic acid (5C) and under an inert atmosphere.
  • the reaction is catalyzed with a palladium catalyst (e.g., Pd(OAc) 2 ).
  • the product (5D) can be purified by methods known in the art (such as HPLC).
  • Other 7-aryl, alkenyl, and alkynyl tetracycline compounds can be synthesized using similar protocols.
  • the 7-substituted tetracycline compounds of the invention can also be synthesized using Stille cross couplings.
  • Stille cross couplings can be performed using an appropriate tin reagent (e.g., R-SnBu 3 ) and a halogenated tetracycline compound, (e.g., 7-iodosancycline).
  • the tin reagent and the iodosancycline compound can be treated with a palladium catalyst (e.g., Pd(PPh 3 ) 2 Cl 2 or Pd(AsPh 3 ) 2 Cl 2 ) and, optionally, with an additional copper salt, e.g., Cul.
  • the resulting compound can then be purified using techniques known in the art.
  • the compounds of the invention can also be synthesized using Heck-type cross coupling reactions.
  • Heck-type cross-couplings can be performed by suspending a halogenated tetracycline compound (e.g., 7-iodosancycline, 6A) and an appropriate palladium or other transition metal catalyst (e.g., Pd(OAc) 2 and Cul) in an appropriate solvent (e.g., degassed acetonitrile).
  • a reactive alkene (6B) or alkyne (6D), and triethylamine are then added and the mixture is heated for several hours, before being cooled to room temperature.
  • the resulting 7-substituted alkenyl (6C) or 7-substituted alkynyl (6E) tetracycline compound can then be purified using techniques known in the art.
  • 5-esters of 9- substituted tetracycline compounds can be formed by dissolving the 9- substituted compounds (8A) in strong acid (e.g. HF, methanesulphonic acid, and trifluoromethanesulfonic acid) and adding the appropriate carboxylic acid to yield the corresponding esters (8B).
  • strong acid e.g. HF, methanesulphonic acid, and trifluoromethanesulfonic acid
  • methacycline (9 A) can be reacted with a phenylboronic acid in the presence of a palladium catalyst such as Pd(OAc) to form a 13 aryl substituted methacycline compound.
  • the resulting compound can then be purified using techniques known in the art such as preparative HPLC and characterized.
  • 7 and 9 aminomethyl tetracyclines may be synthesized using reagents such as hydroxymethyl-carbamic acid benzyl ester.
  • Substituted tetracycline compounds substituted at the 3, 10 or 12a position can be synthesized by contacting the tetracycline compound with a base to deprotonate the hydroxyl group.
  • bases include potassium hydride and sodium hydroxide.
  • the tetracyclines can then be further derivatized by using halides and other reactive species known in the art.
  • alkyl includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (e.g., isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (e.g., cyclopropyl, eyclopentyl, cyclohexyl, cycloheptyl, eyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
  • straight-chain alkyl groups e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, o
  • alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
  • a straight chain or branched chain alkyl has 20 or fewer carbon atoms in its backbone (e.g., C ⁇ -C 20 for straight chain, C 3 -C 20 for branched chain), and more preferably 4 or fewer.
  • Cycloalkyls may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
  • C ⁇ -C 6 includes alkyl groups containing 1 to 6 carbon atoms.
  • alkyl includes both "unsubstituted alkyls" and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sul
  • Cycloalkyls can be further substituted, e.g., with the substituents described above.
  • An "alkylaryl” or an “arylalkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)).
  • the term “alkyl” also includes the side chains of natural and unnatural amino acids.
  • aryl includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
  • aryl includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzotbiazole, benzoimidazole, benzothiophene, methylenedioxophenyl, quinoline, isoquinoline, naphthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine.
  • aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles", “heterocycles,” “heteroaryls” or “heteroaromatics”.
  • the aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and
  • alkenyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
  • alkenyl includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups.
  • alkenyl includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonen
  • alkenyl further includes alkenyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
  • a straight chain or branched chain alkenyl group has 20 or fewer carbon atoms in its backbone (e.g., C2-C20 f° r straight chain, C3-C20 for branched chain).
  • cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
  • C 2 -C 0 includes alkenyl groups containing 2 to 20 carbon atoms.
  • alkenyl includes both "unsubstituted alkenyls" and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
  • alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
  • alkynyl includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted' alkynyl groups.
  • alkynyl further includes alkynyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
  • a straight chain or branched chain alkynyl group has 20 or fewer carbon atoms in its backbone (e.g., C2-C20 f° r straight chain, C3-C20 f° r branched chain).
  • C 2 -C 6 includes alkynyl groups containing 2 to 6 carbon atoms.
  • alkynyl includes both "unsubstituted alkynyls" and
  • substituted alkynyls refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including, e.g., alkylcarbonylamino, ary
  • lower alkyl as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure.
  • Lower alkenyl and “lower alkynyl” have chain lengths of, for example, 2-5 carbon atoms.
  • acyl includes compounds and moieties which contain the acyl radical (CH 3 CO-) or a carbonyl group.
  • substituted acyl includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkenyl, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonyla
  • acylamino includes moieties wherein an acyl moiety is bonded to an amino group.
  • the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
  • alkoxy includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom.
  • alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups.
  • substituted alkoxy groups include halogenated alkoxy groups.
  • the alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate
  • halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc.
  • alkoxyalkyl alkylaminoalkyl
  • thioalkoxyalkyl include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms.
  • amide or "aminocarboxy” includes compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group.
  • alkaminocarboxy groups which include alkyl, alkenyl, or alkynyl groups bound to an amino group bound to a carboxy group. It includes arylaminocarboxy groups which include aryl or heteroaryl moieties bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group.
  • alkylaminocarboxy alkenylaminocarboxy
  • alkynylaminocarboxy and
  • arylaminocarboxy include moieties wherein alkyl, alkenyl, alkynyl and aryl moieties, respectively, are bound to a nitrogen atom which is in turn bound to the carbon of a carbonyl group.
  • amine or "amino” includes compounds where a nitrogen atom is covalently bonded to at least one carbon or heteroatom.
  • alkyl amino includes groups and compounds wherein the nitrogen is bound to at least one additional alkyl group.
  • dialkyl amino includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups.
  • arylamino and “diarylamino” include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively.
  • alkylarylamino alkylaminoaryl or “arylaminoalkyl” refers to an amino group which is bound to at least one alkyl group and at least one aryl group.
  • alkaminoalkyl refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
  • aroyl includes compounds and moieties with an aryl or heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, etc.
  • carbonyl or “carboxy” includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom.
  • moieties which contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
  • esters includes compounds and moieties which contain a carbon or a heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group.
  • ester includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc.
  • alkyl, alkenyl, or alkynyl groups are as defined above.
  • ether includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms.
  • alkoxyalkyl which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group.
  • halogen includes fluorine, bromine, chlorine, iodine, etc.
  • perhalogenated generally refers to a moiety wherein all hydrogens are replaced by halogen atoms.
  • heteroatom includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.
  • hydroxy or "hydroxyl” includes groups with an -OH or -O " X + , where X + is a counterion.
  • polycyclyl or “polycyclic radical” refer to two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings.
  • Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkyl carbonyl, alkenylcarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and
  • thiocarbonyl or "thiocarboxy” includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom.
  • thioether includes compounds and moieties which contain a sulfur atom bonded to two different carbon or hetero atoms.
  • Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls.
  • alkthioalkyls include compounds with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group.
  • alkthioalkenyls and alkthioalkynyls refer to compounds or moieties wherein an alkyl, alkenyl, or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group.
  • oximyl includes moieties which comprise an oxime group.
  • dimeric moiety includes moieties which comprise a second tetracycline four ring structure. The dimeric moiety may be attached to the substituted tetracycline through a chain of from 1-30 atoms. The chain may be comprised of atoms covalently linked together through single, double and triple bonds.
  • the tetracycline ring structure of the dimeric moiety may further be substituted or unsubstituted. It may be attached at the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a, and/or 13 position. Examples of substituted tetracycline compounds with dimeric moieties are shown in Tables 2, 3 and 4.
  • prodrug moiety includes moieties which can be metabolized in vivo.
  • the prodrugs moieties are metabolized in vivo by esterases or by other mechanisms to hydroxyl groups or other advantageous groups.
  • Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).
  • the prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid.
  • prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkyl- amino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides.
  • the structures of some of the substituted tetracycline compounds used in the methods and compositions of the invention include asymmetric carbon atoms.
  • the isomers arising from the chiral atoms e.g., all enantiomers and diastereomers
  • Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis.
  • the structures and other compounds and moieties discussed in this application also include all tautomers thereof.
  • compositions of the invention also pertains to pharmaceutical compositions comprising an effective amount of a substituted tetracycline compound (or pharmaceutically acceptable salt thereof) of the invention and a pharmaceutically acceptable carrier.
  • the effective amount may be effective to treat any one of the dieseases described above, such as for example, IP AS, neurological disorders, or cancer.
  • the pharmaceutical composition may further comprise a neuroprotective agent or a chemotherapeutic agent as described above.
  • pharmaceutical composition includes preparations suitable for administration to mammals, e.g., humans.
  • the compounds of the present invention are administered as pharmaceuticals to mammals, e.g., humans, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
  • phrases "pharmaceutically acceptable carrier” is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals.
  • the carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer'
  • wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • antioxidants examples include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulf ⁇ te, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, ⁇ -tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulf ⁇ te, sodium sulfite and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT),
  • Formulations of the present invention include those suitable for oral, nasal, topical, transdermal, buccal, sublingual, rectal, vaginal, pulmonary and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
  • Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in- ater or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
  • a compound of the present invention may also be administered as a bolus, electuary or paste.
  • the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostea
  • compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
  • compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • Liquid dosage forms for oral administration of the compounds of the invention include phannaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents,
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar- agar and tragacanth, and mixtures thereof.
  • Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
  • Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
  • Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. Sprays also can be delivered by mechanical, electrical, or by other methods known in the art.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
  • dosage forms can be made by dissolving or dispersing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
  • Ophthalmic formulations are also contemplated as being within the scope of this invention.
  • compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial, antiparasitic and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form may be accomplished by dissolving or suspending the drug in an oil vehicle. The compositions also may be formulated such that its elimination is retarded by methods known in the art.
  • Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
  • the preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule fo ⁇ n, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration or administration via inhalation is preferred.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, infrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
  • systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
  • These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
  • Other methods for administration include via inhalation.
  • the tetracycline compounds of the invention may also be administered to a subject via stents.
  • the compounds may be administered through the stent or be impregnated in the stent itself.
  • the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention maybe varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
  • the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 50 mg per kg per day, and still more preferably from about 1.0 to about 100 mg per kg per day. An effective amount is that amount treats a target disease such as, for example, an IP AS, a neurological disorder, or cancer.
  • a target disease such as, for example, an IP AS, a neurological disorder, or cancer.
  • the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
  • certain embodiments of the present compounds can contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids.
  • pharmaceutically acceptable salts is art recognized and includes relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Farm. SCI. 66:1-19).
  • the compounds of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases.
  • pharmaceutically acceptable salts in these instances includes relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention. These salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
  • suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
  • Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. '
  • esters refers to the relatively non-toxic, esterified products of the compounds of the present invention. These esters can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid fonn or hydroxyl with a suitable esterifying agent.
  • Carboxylic acids can be converted into esters via treatment with an alcohol in the presence of a catalyst.
  • Hydroxyls can be converted into esters via treatment with an esterifying agent such as alkanoyl halides.
  • the term also includes lower hydrocarbon groups capable of being solvated under physiological conditions, e.g., alkyl esters, methyl, ethyl and propyl esters. (See, for example, Berge et al., supra.)
  • the invention also pertains, at least in part, to packaged compositions comprising the tetracycline compounds of the invention and instructions for using said compounds for the treatment of diseases which are treatable by the administration of a tetracycline compound having a target therapeutic activity.
  • the invention is further illustrated by the following examples, which should not be construed as further limiting.
  • the contents of all references, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference.
  • Art recognized animal models or in vitro assays for the inflammatory process associated states described herein are used to determine the efficacy of a particular tetracycline compound for a target disease such as an IP AS, neurological disorder, or cancer.
  • Example 1 Synthesis of Tetracycline Compounds The following example discusses methods of synthesizing the tetracycline compounds of the invention. Other compounds of the invention can be synthesized using techniques discussed in the application and/or by using art recognized methods.
  • Detection was by UN absorption with Model 441 absorbance detector operating at 280 nm. Mobile phases used followed a linear gradient from 30% to 100% methanol over 30 minutes at 1.6 mL/min flow rate followed by isocratic elution with MeOH; solvent system A: 0.02 M Na 2 HPO 4 +0.001 M Na 2 EDTA adjusted to pH 4.5 with H 3 PO 3 ; solvent system B: 100% MeOH. Semipreparative HPLC separations used a Waters semipreparative C18 reverse-phase column at a flow rate of 6.4 mL/min. Low and high resolution mass spectra were performed on a PE Mariner spectrometer (Nelson et al, J. Med. Chem. (1993) 36(3):374).
  • the 7-iodo isomer of sancycline was purified by treating the 7-iodo product with activated charcoal, filtering through Celite, and subsequent removal of the solvent in vacuo to produce the 7-isomer compound as a pure yellow solid in 75% yield.
  • the solvent was removed in vacuo to yield the product plus salts.
  • the salts were removed by extraction into 50:25:25 water, butanol, ethyl acetate and dried in vacuo. This solid was dissolved in MeOH and the HCI salt made by bubbling in HCI gas.
  • the solvent was removed in vacuo to yield the product plus salts.
  • the salts were removed by extraction into 50:25:25 water, butanol, ethyl acetate and dried in vacuo. This solid was dissolved in MeOH and the HCI salt made by bubbling in HCI gas. The solvent was removed to produce the product.
  • the crude material was purified by precipitating it with ether (200 ml). The yellow precipitate was filtered and purified using preparative HPLC. The hydrochloride salt was made by dissolving the material in MeOH/HCl and evaporating to dryness. The identity of the resulting solid was confirmed using HPLC, MS, and NMR.
  • the brown solid (9-(2'formyl furanyl)-minocycline, 1 g) was dissolved in 20 mL of methanol and acetic acid (2 mL) and hydroxyethyl piperazine (1 mL) was added and stirred for ten minutes at room temperature. The reaction was quenched with ether (200 mL), and the organic layer was then washed and concentrated to yield a brown oil. The brown oil was the dissolved in methanol (10 mL) and water. The mixture was the chromatographed using a CH 3 CN gradient to yield the product, 2-[4-(9-Minocyclin-2-yl- furan-2-ylmethyl)-piperazin-l-yl]-ethanol. The product was confirmed using MS, NMR, and HPLC.
  • the product was obtained using preparative HPLC and converted to the HCI salt. The product was confirmed using mass spectra and NMR.
  • the brown solid (9-(2'formyl furanyl)-minocycline, 1 g) was dissolved in 20 mL of methanol and acetic acid (2 mL) and N'-benzyl-N,N-dimethyl ethylenediamine (1 mL) was added and stirred for ten minutes at room temperature. The reaction was quenched with ether (200 mL), and the organic layer was then washed and concentrated to yield a brown oil. The brown oil was the dissolved in methanol (10 mL) and water.
  • Triethylamine was added to a solution of doxycycline (1 g, 2.2 mmole) in 15 ml of methanol to bring the pH to about 9. Then, 426 mg of sodium borohydride (5 eq) was added to this mixture portionwise. The resulting reaction mixture was stirred at room temperature for several hours. The reaction was monitored by analytical HPLC and LCMS [MS: 445(for starting material) and MS 447(for product)]. The solvent was removed and the residue was diluted with water. The aqueous solution was then extracted with n-butanol (2x). The combined organic fractions were evaporated under reduced pressure to give the CI alcohol.
  • COS-1 and CHO-K1 cell suspensions were prepared, seeded into 96-well tissue culture treated black- walled microtiter plates (density determined by cell line), and incubated overnight at 37°C, in 5% CO 2 and approximately 95% humidity. The following day, serial dilutions of drug were prepared under sterile conditions and transfe ⁇ ed to cell plates. Cell/Drug plates were incubated under the above conditions for 24 hours. Following the incubation period, media/drug was aspirated and 50 ⁇ l of Resazurin (0.042 mg/ml in PBS w/Ca and Mg) was added. The plates were then incubated under the above conditions for 2 hours and then in the dark at room temperature for an additional 30 minutes.
  • Resazurin 0.042 mg/ml in PBS w/Ca and Mg
  • the following assay was used to determine the efficacy of the tetracycline compounds against gram positive (S. aureus RN450) and gram negative (E. coli ML308 225) bacteria. 2 mg of each compound was dissolved in 100 ⁇ l of DMSO. The solution was then added to cation-adjusted Mueller Hinton broth (CAMHB), which resulted in a final compound concentration of 200 ⁇ g per ml. The tetracycline compound solutions were diluted to 50 ⁇ L volumes, with a test compound concentration of .098 ⁇ g/ml. Optical density (OD) determinations were made from fresh log-phase broth cultures of the test strains. Dilutions were made to achieve a final cell density of 1x10 CFU/ml.
  • CAMHB cation-adjusted Mueller Hinton broth
  • MIC was defined as the lowest concentration of ithe tetracycline compound that inhibits growth.
  • Table 3 compounds with MIC of greater than 4 ⁇ g/ml are indicated with *, and compounds with MIC less than or equal to 4 ⁇ g/ml are indicated with **.
  • Table 3 (Continued), compounds with MIC of greater than * ⁇ g/ml are indicated with *, and compounds with MIC less than or equal to 8 ⁇ g/ml are indicated with **.
  • Example 4 In vitro Anti-Inflammatory Assay: Lipopolysaccharide Stimulation of Macrophage Assay (LSM Assay)
  • This assay was used to determine the anti-inflammatory effect of tetracycline compounds of the invention by determining the modulation of nitric oxide, interleukin- 10 and interleukin- 12 synthesis in the J774 cell line, according to a literature procedure (D'Agostino P. et al. hit Immunopharmacol. 2001 Sep;l(9-10): 1765-76). J774.2 cells were stimulated with 100 ng/ml lipopolysaccharide (LPS). Nitrite, the spontaneous degradation product of nitric oxide, is measured in cell supernatants using the Greiss Reaction. In the experimental conditions, test tetracycline compounds were added 30 minutes prior to LPS stimulation.
  • LPS lipopolysaccharide
  • Cytotoxicity is determined using Resazurin metabolism.
  • a 96-well black-walled plate (except for the bottom row) was seeded with 100 ⁇ l of a 2.5 x IO 6 cells /ml suspension and incubated for two hours at 37 °C and 5% CO 2 .
  • test compounds were prepared at a concentration of 139 ⁇ g/ml, in 1.25% DMSO, a 2.5x concentration ready for addition to the cells.
  • Resazurin fluorescence 50 ⁇ l of Resazurin was added to each well (0.042 mg/ml in PBS w/Ca and Mg). The plate were then incubated for 45 mins, 37°C, 5% CO 2 , and for 30 minutes at room temperature. The plate was then read for Resazurin fluorescence.
  • Example 5 In vitro Neuroprotection Assay: Protection of Cultured Cortical Neurons from Excitotoxic Injury Induced by NMDA (NE Assay)
  • This assay shows the ability of tetracycline derivatives to protect cultured murine cortical neurons from excitotoxic injury induced by NMDA exposure.
  • Primary cortical astrocyte cultures were prepared from one-day old mice, as described in the literature procedure (Tikka, TM et al. J Immunol. 2001 Jun 15;166(12):7527-33). After decapitation, the forebrain cortices were collected, cleaned from meninges and, after mincing, dissociated by incubation in papain/Dnase solution followed by trituration.
  • the dissociated cells were suspended in a culture medium consisting of Eagle's minimal essential medium (MEM) with 10% heat-inactivated fetal bovine serum and glutamine (2mM) and plated in 75 cm 2 cell culture flasks. The medium was replaced with fresh culture medium at day 7. At confluence (day 12-15), the astrocytes were trypsinized and re-plated into 24-well culture vessels. On day 7-8, the neurons were cultured on top of these confluent astrocyte monolayers.
  • MEM Eagle's minimal essential medium
  • 2mM heat-inactivated fetal bovine serum and glutamine
  • Cortical neuron suspensions were prepared from embryonic day 17 mice. The cortices were collected and meninges removed. The tissue was minced into small pieces and incubated in trypsin solution. The tissue was suspended using a pipette and after centrifugation resuspended and plated on top of astrocyte cultures at a density of 250,000 cells / well to 24-well culture vessel in Eagle's minimal essential medium (MEM, Earle's salts) supplemented with 20 mM glucose, 2 mM glutamine, 10 % fetal bovine serum, and 10 % heat-inactivated horse serum (HS).
  • MEM Eagle's minimal essential medium
  • HS heat-inactivated horse serum
  • the cell viability was assessed by measuring lactate dehydrogenase (LDH) release 24 hours after starting the exposure.
  • LDH release to the culture medium was measured from cell-free medium using Sigma LDH reagent employing kinetic measurement of conversion of lactate to pyruvate using NADH as a cofactor.
  • the rate of increase in absorbance at 340 nm was directly proportional to the activity of LDH in the sample, and was measured with a Labsystems Multiskan ELISA reader.
  • the compounds for which demonstrated good neuroprotection in this assay include Compounds C, D, G, H, M, Q, BP, CD, CW, EN, IE, JC, JD, KF, LJ, and OM from Table 3.
  • Example 6 In vitro Neuroprotection Assay: Neuroprotection of an SH-SY5Y Neuroblastoma Cell Line (NSN Assay) In this example, the ability of tetracycline compounds to protect human neuroblastoma cells from oxidative stress is determined.
  • Human SH-SY5Y neuroblastoma cells are maintained in Dulbecco's modified Eagle's medium supplemented, with 10% fetal bovine serum and 2% penicillin- streptomycin, and incubated at 37°C in a humidified atmosphere with 5% CO 2 according to a literature procedure (Zhu, S et al. Nature. 2002 May 2;417(6884):74-8).
  • the cells are routinely sub-cultured using 0.05% trypsin-EDTA solution.
  • the cells are seeded at 10 3 cells/well in 96-well plates and grown until each well is 75-80 % confluent.
  • the SHSY-5Y cells are incubated with various doses of hydrogen peroxide for 24 hours in order to identify a dose for screening that provides a model for a chronic injury to the cells.
  • An optimal dose should result in approximately 70% loss in cell survival as compared to the control after 24 hours.
  • the final concentration of H 2 O 2 to be used in the assay will be less than 300uM.
  • the ability of the tetracycline compounds of the invention to protect dopaminergic cells is used to predict the ability of the tetracycline compounds to treat Parkinson's Disease.
  • MES23.5 cells or primary cultures of embryonic rat mesencephalon are cocultured with purified rat microglia and treated with lipopolysaccharide, PD IgG or dopa-quinone-modified MES 23.5 cell membranes to induce microglia-mediated injury according to literature procedure (Le W. et al, J Neurosci. 2001 Nov l;21(21):8447-55).
  • Detailed dosage and temporal response of tetracycline derivatives treatment is carried out.
  • the neuroprotection is examined in the cultures by quantitatively counting the number of tyrosine hydroxylase (TH)-positive cells or by biochemical determination of TH activity in a blind fashion. Each compound will be tested three times in a triplicate manner. To determine the inhibitory effects of the tested tetracycline derivatives on microglia, the culture media is collected for measuring the levels of TNF- ⁇ released from microglia, a biochemical marker of microglial activation. The observed biological activity, neuroprotection of dopaminergic cells and inhibition of microglial activation is used to develop a structure activity relationship (SAR).
  • SAR structure activity relationship
  • Example 8 In vitro Neuroprotection Assay: Cytochrome C Release Assay (CCR Assay)
  • This example shows the ability of tetracycline compounds of the invention to inhibit cytochrome C release.
  • Mouse liver mitochondria are prepared as described by Luo et al. (Cell 94,481- 490 (1998)) and resuspended in MRM buffer (250 mM sucrose, 10 mM HEPES, pH 7.5, 1 mM ATP, 5 mM sodium succinate, 80mM ADP, 2 mM K2 HPO4 ) at a concentration of 0.5 mg/mL, according to a literature procedure (Zhu S. et al. Nature. 2002 May 2;417(6884):74-8).
  • Rat liver mitochondria are isolated from 4-6-month-old Fischer 344 X brown Norway FI rats by differential centrifugation as described.
  • Non-synaptosomal rat brain mitochondria are prepared from forebrains of 8 week old rats by ficoll gradient purification.
  • cytochrome C release To assay the effects of the tetracycline compounds on cytochrome C release, a 25 ⁇ l aliquot of 0.5mg/mL mitochondrial extract preparation is preincubated with the test substituted tetracycline compounds for 5 minutes in MRM buffer. To this CaCl 2 or other inducers of cytochrome C release, such as purified Bid protein, are added. The mixtures are incubated for 30 minutes to 1 hour at 37 °C. The mixes are then centrifuged at 10,000g at 4 °C for 10 minutes and the supernatant is evaluated for release of cytochrome C by Western blot.
  • Example 9 In vivo Amylotropic Lateral Sclerosis Mouse Model
  • the tetracycline compounds of the invention are tested in vivo
  • ALS mice (Jackson Laboratories) are injected intraperitoneally daily with saline as a control or the test tetracycline compounds according to a literature procedure (Zhu S et al. Nature. 2002 May 2; 417 (6884):74-8).
  • the tetracycline compounds may be given by other routes including oral administration.
  • Strength and coordination are evaluated weekly by a standard Rotarod test. The disease is defined as the first day a mouse can not remain on the Rotarod for 10 minutes at 15 r.p.m. Mortality is scored as age of death or age when the mouse is unable to right itself within 30 seconds.
  • Tissues from animals can be evaluated for cytochrome C release, caspase activation and iNOS protein levels using Western blots and histochemical staining. Additionally, methods of detecting transcript levels (ie. Northern blots, quantitative PCR or microarrays) are used to evaluate message levels.
  • Example 10 In vivo Huntington's Disease Mouse Model
  • the tetracycline compounds of the invention are tested in vivo for the treatment of Huntington's disease using a mouse model.
  • R6/2 mice (Jackson Laboratories, Bar Harbor, Maine) are randomly assigned to three groups, according to a literature procedure (Chen M et al. Nat Med. 2000 Jul;6(7):797- 801).
  • mice are treated with the test tetracycline compounds.
  • the test tetracycline compounds can be given by a number of routes. Motor performance is evaluated weekly from 5 to 13 weeks on a Rotarod), at 5 and 15 rpm. If the mouse remains on the rod for 10 minutes the test is completed and scored as 10 minutes.
  • Tissues from animal are evaluated for cytochrome C release, caspase activation and iNOS protein levels using Western blots and histochemical staining. Additionally, methods of detecting transcript levels (i.e., Northern blots, quantitative PCR or microarrays) are used to evaluate message levels.
  • mice model is used to determine the ability of the tetracycline compounds to treat Parkinson's Disease.
  • Other models which can be used are described in Wu D.C. et al. J Neurosci. 2002 Mar 1;22(5):1763-71 and Du Y. et al. PNAS 2001 Dec 4;98(25): 14669-74.
  • Eight-week-old male C57BLy6 are used in the example.
  • Mice (5-7 per group) are administered the test tetracycline compounds by any of a number or routes including oral gavage before, during, and after l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) administration.
  • MPTP l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine
  • the MPTP-treated groups receive four injections of MPTP-HCl (20 mg/kg, i.p.) in saline at 2-h intervals in a single day (four injections total) and are killed 7 days after the last injection. Tissues from each animal are evaluated for cytochrome C release, caspase activation, tyrosine hydroxylase and iNOS protein levels using Western blots and histochemical staining. Additionally, methods of detecting transcript levels, such as Northern blots, quantitative PCR and microarrays, are used to evaluate message levels.
  • a rat model is used to determine the ability of the tetracycline compounds to treat Multiple Sclerosis.
  • Other models which can be used are described in Brundula V. et al. Brain 2002 Jun;125(Pt 6):1297-308 and Popovic N. et al. Ann Neurol. 2002 Feb;51(2):215-23.
  • This example is performed on 6- to 8-week-old female DA rats.
  • the recombinant extracellular immunoglobulin domain of myelin oligodendrocyte protein (MOG ) is expressed and purified from E. coli.
  • the rats are immunized subcutaneously (s.c.) at thebase of the tail with either 10 ⁇ g MOG in complete Freund's adjuvant or 100 ⁇ g MOG emulsified in incomplete Freund's adjuvant in a total volume of 100 ⁇ l.
  • the animals are weighed and examined daily for clinical signs of experimental autoimmune encephalomyelitis (EAE).
  • EAE experimental autoimmune encephalomyelitis
  • test tetracycline compounds are freshly dissolved in distilled water or phosphate-buffered saline (PBS) and are administered daily by intraperitoneal (i.p.) injections at a dosage of 45 mg/kg rat body weight.
  • PBS phosphate-buffered saline
  • the animals are scored for hind limb paralysis by standard methods. Tissues from each animal are evaluated for demyelination, cytochrome C release, caspase activation, tyrosine hydroxylase and iNOS protein levels using Western blots and histochemical staining. Additionally, methods of detecting transcript levels such as Northern blots, quantitative PCR and microarrays, are used to evaluate message levels.
  • a rat model is used to determine the ability of the tetracycline compounds to treat stroke.
  • Other models which can be used are described in Yrjanheikki J. et al. PNAS 1998 Dec 22;95(26): 15769-74 and Yrjanheikki J et al. PNAS 1999 Nov 9;96(23): 13496-500.
  • Male Sprague-Dawley rats weighing 210-250 grams are housed at a standard temperature and in a light-controlled environment with ad libitum access to food and water. The animals are divided randomly into tetracycline-treatment and control groups.
  • Focal cerebral ischemia is produced by introduction of an intraluminal nylon thread.
  • the rats are anesthetized with 5% (vol/vol) isoflurane (70% N 2 O/30% O 2 ); during the operation, isoflurane concentration was reduced to 0.5%.
  • the rectal temperature is maintained between 37.0 °C and 37.5 °C with a heating pad.
  • the right common carotid artery is exposed, and the external carotid artery ligated.
  • a 0.25-mm monofilament nylon thread (Kuusamo Uis-tin, Kuusamo, Finland) with the tip blunted with sandpaper is inserted 22-23 mm into the internal carotid artery up to the MCA. After 90 minutes of ischemia, the MCA blood flow is restored by removing the thread.
  • a polyethylene catheter is inserted into the femoral artery.
  • Arterial blood pressure, PO 2 ,PCO 2 , pH, and plasma glucose are measured during and 15 minutes after ischemia.
  • Section of brain tissue are evaluated to determine the size of the infarct.
  • Tissues from each animal are evaluated for demyelination, cytochrome C release, caspase activation, tyrosine hydroxylase and iNOS protein levels using Western blots and histochemical staining. Additionally, methods of detecting transcript levels such as Northern blots, quantitative PCR and microarrays are used to evaluate message levels.
  • a rabbit cornea is used to determine the ability of the tetracycline compounds to treat cancer.
  • the cornea provides an avascular matrix into which blood vessels can grow and be quantitated.
  • Other models which can be used are described in Tamargo RJ et al. Cancer Res. 1991 Jan 15;51(2):672-5 and Masumori N. et al. Adv Dent Res. 1998 Nov;12(2):l 11-3.
  • the corneas of anesthetized New Zealand white rabbits are implanted with a serially transplantable tumor syngeneic to the animals.
  • the test tetracycline compound are administered orally, intravenously, intraperitoneally or by using a controlled release polymer.
  • the angiogenesis response of the transplanted tumor material is quantitated by measuring both vessel length, number of vessels and the span of blood vessels.
  • Example 15 In vitro Cancer Assay: Matrigels as Model of Angiogenesis
  • matrigels are used to determine the ability of the tetracycline compounds to treat cancer.
  • a solid gel of basement proteins is prepared from a Engelbreth Holm-Swarm (EHS) mouse tumor.
  • EHS Engelbreth Holm-Swarm
  • the gel forms an in vitro analog of the basement membrane.
  • Endothelial cells, in solution are placed on top of the gel, allowing the cells to align and form tube-like structures which are observed under an inverted light microscope.
  • Tube formation is a multi-step process involving cell adhesion, migration, differentiation and growth.
  • the test tetracycline compounds are added to the matrigel. The ability of the test tetracycline compounds to alter cell adhesion, migration, differentiation and growth is determined by observing the effects of the compounds on the cells of the matrigel.
  • Example 16 In vivo Cancer Mouse Model: Metastasis in Immunosuppressed Mice
  • immunosuppressed mice are used to determine the ability of the tetracycline compounds to treat cancer.
  • Other models which can be used are described in Parangi S. et al. PNAS 1996 Mar 5;93(5):2002-7 and Seftor R.E. et al. Clin Exp Metastasis. 1998 Apr;16(3):217-25.
  • frnmunosuppressed mice (scid/scid females) are injected via the tail vein with C8161 cells, which results in a large number of lung metastases.
  • Test tetracycline compounds are administered intravenously, intraperitoneally or orally. After 24 days, the animals are sacrificed and number of metastases to the lungs quantitated.
  • Example 17 In vivo Aortic Aneurysms Model
  • mice are used to determine whether substituted tetracycline compounds are effective agents to treat aortic aneurysms, as described in Prall, et al. J. Vase. Surg. 2002:35: 923-929.
  • Other models which can be used are described in Curci, et al. J. Vase. Surg. 2000; 31: 326-342.
  • C57BL/6 strain mice are given the substituted tetracycline compound beginning at 7 weeks of age prior to the induction of an aortic aneurysm.
  • a separate group of mice is given the substituted tetracycline compound immediately following the induction of the aortic aneurysm.
  • the tetracycline compound is dissolved in the drinking water of the mice and prepared in concentrations estimated based on the average weight of a C57BL/6 mouse and the average daily intake of water for a mouse.
  • Aortic aneurysms are induced in mice at 8 weeks of age according to the procedure described in Prall et al, supra. Briefly, mice undergo anesthesia and the entire infrarenal abdominal aorta is isolated from the surrounding retroperitoneal structures.
  • the diameter of the aorta is measured to the nearest micrometer using a video micrometer. Diameter measurements are taken at the maximal aortic diameter.
  • the aneurysm is induced by bathing the aorta with 0.25 mol/L CaCl for 15 minutes, and then rinsing with 0.9% NaCI. Control mice are just bathed in NaCI.
  • blood samples are taken from the mice to assess the level of the substituted tetracycline compound.
  • Ten weeks following the surgery a laparotomy is repeated and the infrarenal aorta is isolated and measured. The initial and final aortic diameters are compared.
  • the presence of an aortic aneurysm is defined as an increase in the aortic diameter of greater than 50% of the original diameter.
  • Data from the aortic aneurysm and the determined blood serum level of the substituted tetracycline compound are then compared among the experimental and control groups to determine whether the substituted tetracycline compound is able to suppress an aortic aneurysm.
  • Example 18 In vivo Diabetic Complications Rat Model
  • rats are used to determine if tetracycline compounds are effective agents that can be used to treat diabetic complications.
  • Other models which can be used are described in Ryan et al. Curr. Med. Chem. 2001;8(3):305-316.
  • Niral-free adult male Sprague-Dawley rats are distributed into nine groups, with 5-7 rats in each group. Diabetes is induced in each rat by IN. administration of streptozotocin (70 mg/kg body weight).
  • a weekly diagnostic test including a glucose test strip (Tes-Tape, Eli Lilly), is given to determine the diabetic status of each rat.
  • One week after the diabetes induction diabetic rats are given a daily oral dose, including but not limited to 15mg/kg, of the tetracycline compound for a period of 3 weeks.
  • mice After the 3 week period, rats are sacrificed, anaesthetized with pentobarbital and their blood is collected by cardiac puncture. Serum samples from the collected blood are then analyzed for glucose concentration using a glucose oxidase (Sigma Chemical Co., St. Louis, MO). At sacrifice, skins from the rats are also removed for further study. Skin samples are homogenized and protein extracts from the tissue are removed through standard protocols known in the art. The protein extract from the skin of the diabetic rats is examined for collagenase and gelatinase activity to determine if the tetracycline compound is effective at reducing and/or inhibiting MMP activity in diabetic rats. Collagenase activity can be determined by a standard collagenolysis assay as described in Golub et al. J. Peridontal Res. 1983:18:23. Gelatinase activity can be determined by standard methods, including those described in McCroskey et al. Biochem J. 1975; 152: 131.
  • rats are used to determine if tetracycline compounds are effective agents that can be used to treat arteriosclerosis.
  • Other models which can be used are described in Bendeck, et al. Arner. J. Path. 2001 : 160(3): 1089-1095.
  • Sprague-Dawley rats (3 to 4 months old) are anaesthetized by intraperitoneal injection of xylazine and ketamine.
  • a balloon catheter injury of the left common carotid artery is performed as described in Bendeck et al. Circ. Res. 1994:75: 539-545.
  • Tetracycline compounds are administered to the rats through their drinking water at a dose of 30 mg/kg beginning 24 hours prior to the surgery described above.
  • Rats are then sacrificed at various time points after the surgery based on previous studies that have determined the kinetics of the injury response.
  • Medial smooth muscle cell (SMC) proliferation is measured in the media (2, 4, 7, and 14 days) and intima (7 and 14 days) as detennined in Clowes et al. Lab. Invest. 1983:49:327-333.
  • Migration of cells from media to the intima and MMP activity is measured at 4 days (Bendeck et al, 1994, supra).
  • Cells are labeled using a 50 mg pellet of 5-bromo-2'deoxyuridine according to Bendeck et al, 2002, supra).
  • SMC replication is determined following sacrifice by immunostaining carotid cross-sections for BrdU and determining the percentage of BrdU-labeled cells as described in Strauss et al. J. Clin. Invest. 1992:90: 2044-2049.
  • SMC migration is determined as described in Bendeck et al. 2002, supra.
  • MMP activity is measured by gelatin zymography as described in Bendeck et al 1994, supra.
  • Example 20 In vivo Acute Respiratory Distress Syndrome Pig Model
  • hybrid pigs are used to determine the ability of the tetracycline compounds to treat ARDS.
  • Other models which can be used are described in Carney D.E. et al Circulation, 1999 Jul 27;100(4):400-6.
  • Yorkshire hybrid pigs (15 to 20 kg) are anesthetized with sodium pentobarbital and a bolus infusion of pancuronium bromide.
  • the technique for initiating CPB is described in the literature (e.g., Picone A.L. et al. Ann Thorac Surg.
  • LPS lipopolysaccharide
  • mice are used to determine the ability of the tetracycline compounds to treat endotoxic shock.
  • Other models which can be used are described in Milano S. et al. Antimicrob Agents Chemother. 1997 Jan;41(l):117-21 and Shapira L. et al. Infect Immun. 1996 Mar;64(3):825-8.
  • Sabra mice are injected with Salmonella typhosa lipopolysaccharide (LPS) intravenously as a model for endotoxic shock.
  • LPS Salmonella typhosa lipopolysaccharide
  • LPS is dissolved in a sterile pyrogen-free saline solution and dispersed by brief sonication.
  • the experimental animals are given a solution containing the tetracycline compounds by gavage 20 minutes prior to intravenous LPS injection.
  • the tetracycline compounds may, however, be given by other routes.
  • Drug administration is repeated 6 and 24 hours after the LPS injection but at half of the original dose.
  • the control animals receive saline.
  • Mouse mortality is monitored twice daily for 72 hours, and in some experiments, momtoring is continued once daily for up to 3 weeks.
  • TNF-c. levels in serum mice are challenged with 500 mg of LPS intravenously. Simultaneously, 1 ml of a solution containing the test tetracycline compound is given by gavage to the experimental animals, while the control animals receive saline.
  • the animals are bled from the infraorbital plexus 2 hours after the LPS challenge, and the levels of TNF-c- in the serum are determined by two-site enzyme-linked immunosorbent assay (ELISA) with anti-mouse TNF-c. antibodies. Additional markers of inflammation such as NO are also assayed using standard techniques.
  • ELISA enzyme-linked immunosorbent assay
  • Example 22 In vivo Wound Healing Rat Model
  • rats are used to determine if substituted tetracycline compounds are effective agents that can be used to help wounds heal.
  • Other models which can be used are described in Pirila, et al. Curr. Med. Chem. 2001;8:281-294.
  • Sprague-Dawley rats (6 months old) are either sham operated or ovariectomized. After 120 days, both control and ovariectomized are anaesthetized with xylazine and ketamine. The dorsal skin is shaved and wiped with a 75% alcohol solution, and washed with 0.9% saline. Eight full thickness skin wounds are made in the dorsal thorax using a 6 mm diameter circular biopsy punch. Wounds are allowed to heal. The wound biopsies are standardized by coring the skin until the biopsy punch reaches the cutaneous muscle. White petroleum is directly applied to the wound immediately after the injury, and daily thereafter for 7 days.
  • Rats which were operated upon receives a daily dose of the tetracycline compounds orally by gavage at 15 mg/kg body weight). Rats are anaesthetized 7 days following surgery, blood samples are collected, and the skin containing four wounds is excised for histological analysis. Collagenase and gelatinase activity is measured from the excised wounds according to the methods described in Golub et al.Ann. N.Y. Acad. Sci. 1994: 732: 96. Wound tissue is also removed under sterile conditions for sectioning purposes. Immunohistochemistry and in situ hybridization is then performed on the sections, as described in Pirila, et a/., supra. Example 23: In vivo Traumatic Brain Injury Mouse Model
  • mice are used to determine if tetracycline compounds are effective agents that can be used to treat traumatic brain injury.
  • Other models which can be used are described in Meijia, et al. Neurosurgery. 2001:48(6):1393-1399.
  • adult C57BL/6 mice are injected intraperitoneally with tetracycline compounds at a dose of 45 mg/kg body weight.
  • adult C57BL/6 mice are anaesthetized with isoflurane in 70% N 2 O and 30% O 2 .
  • Mice then undergo an atraumatic craniotomy removing the right parietal bone to the coronal, lateral to the sagittal, and anterior to the lamboid suture. Laterally, the craniotomy is extended to the temporalis muscle insertion.
  • mice For the pretreatment and posttreatment test groups of mice, beginning 30 minutes after the trauma, the mice receive a dose of the tetracycline compound every 12 hours, at a dose of 90 mg/kg body weight for the first 24 hours after trauma, and then 45 mg/kg body weight thereafter until the mice are sacrificed.
  • mice After sacrifice, the mice are perfused with 4% paraformaldehyde and their brains are removed and frozen in chilled isopentane after cryoprotection in 30% sucrose. Sections are prepared and immunohistochemistry is performed in them using specific antibodies against caspase- 1 and caspase-3.
  • rats are used to determine if tetracycline compounds are effective agents that can be used to treat arthritic-osteoporosis.
  • Models which can be used are described in Ramamurthy, et al. Curr. Med. Chem. 2001;8:295-303, as is detailed below.
  • Rats are divided into experimental and control groups. Designated groups receive tetracycline compounds through oral administration at 2 mg/day. Ninety days following the initial administration of the tetracycline compounds, rats are anesthetized with a mixture of ketamine and rompun, their blood is drawn, and they are sacrificed.
  • RNA is extracted from the femurs according to standard methods. Extracted mRNA is analyzed by performing a Northern blot analysis using probes to known bones transcripts, including type I collagen, osteopontin, and collagenase. Levels of RNA are quantified by dot blot analysis. Levels are compared among the experimental and control groups.
  • Bone mineral density (BMD) among the control and experimental gorups is determined on the metaphyseal region of the proximal tibia at a site that is equidistant between the proximal articular surface and the midpoint of the diaphysis.
  • a single, 0.5mm slice pe ⁇ endicular to the long axis of the tibia shaft is collected and analyzed.
  • the BMC and BMD area properties are determined using software available in the field. Bones are also sectioned and their histology studied according to the methods of Ramamurthy et al, supra.
  • Example 25 In vitro Motor Neuron Disease Assay
  • spinal cord cultures are used to test the ability of tetracycline compounds to reduce apoptotic neuronal death and microglial activation, as described in Tikka et al. Brain. 2002: 125 (4): 722-731.
  • CSF neurotoxic cerebral spinal fluid
  • MND motor neuron disease
  • spinal cord cultures are exposed to CSF samples (medium containing 25% CSF in DMEM and 1% HS-HIU) for 24 hours.
  • spinal cord cultures are fixes with 4% paraformaldehyde, rinsed in 0.1M phosphate-buffered saline and incubated with the nuclear binding- dye bis-benzimide for 5 minutes. This nuclear dye reveals cells undergoing apoptotic death.
  • the stained cultures are also processed for immunohistochemical analysis of neurofilament phosphorylation using antibodies against neuro filaments. Results are compared between the control group of cells and those cells incubated with tetracycline compounds.
  • MMP-9 human MMP-9 (total) Immunoassay from R&D Systems. MMP-9 levels were calculated based on a standard curve of purified MMP-9 dilution samples run simultaneously in the ELISA plate. This assay detected both the 92 kDa pro- and 82 kDa active forms of MMP-9. Compounds which showed some inhibition of MMP-9 production are indicated with "*" in Table 4. Compounds which showed good inhibition of MMP-9 production are indicated with "**.” Compounds which showed very good inhibition of MMP-9 production are indicated with "***.” Compounds which showed superior inhibition of MMP-9 production are indicated with "****.”

Abstract

L'invention concerne des méthodes et des composés de traitement de maladies avec des composés de tétracycline possédant une activité thérapeutique ciblée.
PCT/US2004/001036 2003-01-16 2004-01-16 Composes de tetracycline possedant des activites therapeutiques ciblees WO2004064728A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44114103P 2003-01-16 2003-01-16
US60/441,141 2003-01-16

Publications (2)

Publication Number Publication Date
WO2004064728A2 true WO2004064728A2 (fr) 2004-08-05
WO2004064728A3 WO2004064728A3 (fr) 2004-12-16

Family

ID=32771908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001036 WO2004064728A2 (fr) 2003-01-16 2004-01-16 Composes de tetracycline possedant des activites therapeutiques ciblees

Country Status (1)

Country Link
WO (1) WO2004064728A2 (fr)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534300A2 (fr) * 2002-07-12 2005-06-01 Paratek Pharmaceuticals, Inc. Composes de tetracycline substituee en 3, 10, et 12a
US7001918B2 (en) * 2001-03-13 2006-02-21 Paratek Pharmaceuticals, Inc. 7-pyrrolyl tetracycline compounds and methods of use thereof
WO2006047671A2 (fr) * 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines et procedes d'utilisation
WO2006047756A2 (fr) * 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues
WO2007014154A2 (fr) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. Tetracyclines 10-substituees et leurs procedes d'utilisation
EP1778252A2 (fr) * 2004-08-11 2007-05-02 Donald L. Barbeau Composes pharmaceutiques non cardiotoxiques
JP2007520482A (ja) * 2004-01-15 2007-07-26 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物の芳香族ａ環誘導体
JP2008500391A (ja) * 2004-05-21 2008-01-10 ザ プレジデント アンド フェローズ オブ ハーバード カレッジ テトラサイクリンおよびそれらの類似物の合成
WO2008079363A2 (fr) * 2006-12-21 2008-07-03 Paratek Pharmaceuticals, Inc. Utilisation de composés à base de tétracycline substituée dans le traitement d'affections cutanées inflammatoires
JP2008530106A (ja) * 2005-02-15 2008-08-07 ワイス ９−置換テトラサイクリン
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
JP2009507793A (ja) * 2005-08-31 2009-02-26 ワイス グリシルサイクリンの９−アミノカルボニル置換誘導体
JP2009522380A (ja) * 2006-01-10 2009-06-11 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッド 抗腫瘍活性を有するタキソール誘導体
JP2010513527A (ja) * 2006-12-21 2010-04-30 パラテック ファーマシューティカルズ インコーポレイテッド 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
EP2307027A1 (fr) * 2008-07-11 2011-04-13 Neumedics Dérivés de tétracycline présentant une activité antibiotique réduite et des bénéfices neuroprotecteurs
EP2341771A1 (fr) * 2008-09-19 2011-07-13 Paratek Pharmaceuticals, Inc. Composés de tétracycline utilisés dans le traitement de la polyarthrite rhumatoïde et méthodes thérapeutiques associées
CN102204921A (zh) * 2011-04-14 2011-10-05 苏州大学 一种四环素类衍生物在制备放疗增敏药物中的应用
US8293920B2 (en) 2006-10-11 2012-10-23 President And Fellows Of Harvard College Synthesis of enone intermediate
CN102821769A (zh) * 2010-03-10 2012-12-12 大学健康网络 替加环素用于治疗癌症的用途
WO2013013505A1 (fr) 2011-07-26 2013-01-31 山东亨利医药科技有限责任公司 Composé tétracycline substitué par 9-aminométhyle
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
CN103142624A (zh) * 2013-03-01 2013-06-12 西南大学 抗生素替加环素在制备抗癌药物中的应用
US8486921B2 (en) 2006-04-07 2013-07-16 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
US8513219B2 (en) 2007-05-02 2013-08-20 Queen Mary & Westfield College, University Of London Substituted phosphonates and their use in decreasing amyloid aggregates
JP2014221820A (ja) * 2008-03-28 2014-11-27 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物の経口製剤および注射可能な製剤
US9073829B2 (en) 2009-04-30 2015-07-07 President And Fellows Of Harvard College Synthesis of tetracyclines and intermediates thereto
US9518011B2 (en) 2012-11-21 2016-12-13 Nippon Soda Co., Ltd. Recording material produced using non-phenol compound
EP3256135A4 (fr) * 2015-02-09 2018-06-27 Yeda Research and Development Co. Ltd. Procédés pour prévenir des infections secondaires
CN109563035A (zh) * 2016-06-22 2019-04-02 山东亨利医药科技有限责任公司 9-氨基甲基取代的四环素类化合物的晶型及其制备方法
WO2019241466A1 (fr) 2018-06-13 2019-12-19 Texas Tech University System Tétracycline modifiée pour le traitement des troubles de l'usage de l'alcool, de la douleur et d'autres troubles impliquant des processus inflammatoires potentiels
WO2022079204A1 (fr) 2020-10-14 2022-04-21 Institut Du Cerveau Et De La Moelle Epiniere Dérivés de tétracycline pour le traitement de maladies neurodégénératives ou neuroinflammatoires
WO2022167954A1 (fr) * 2021-02-03 2022-08-11 Skybio Llc Transporteur chimiquement couplé pour médicaments bioactifs à faible hydrophobicité dans le système nerveux central
WO2024008951A1 (fr) 2022-07-08 2024-01-11 Icm (Institut Du Cerveau Et De La Moelle Épinière) Dérivés de tétracycline

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052575A1 (fr) * 1997-05-20 1998-11-26 The Trustees Of Columbia University In The City Of New York Utilisation d'inhibiteurs de la proteinase pour le traitement de l'emphyseme pulmonaire
WO2000016783A1 (fr) * 1998-09-21 2000-03-30 The Research Foundation Of State University Of New York Methode de prevention des lesions pulmonaires aiguës
WO2001062261A1 (fr) * 2000-02-25 2001-08-30 Arakis Ltd. Inhibiteurs de metalloproteinase utilises dans le traitement des maladies respiratoires
WO2002072031A2 (fr) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitue utilises en tant qu'antifongiques synergiques
WO2002072022A2 (fr) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues, en tant qu'agents antifongiques
WO2003061767A1 (fr) * 2002-01-25 2003-07-31 Atopic Pty Ltd Techniques et compositions destines au traitement de l'asthme et de troubles associes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052575A1 (fr) * 1997-05-20 1998-11-26 The Trustees Of Columbia University In The City Of New York Utilisation d'inhibiteurs de la proteinase pour le traitement de l'emphyseme pulmonaire
WO2000016783A1 (fr) * 1998-09-21 2000-03-30 The Research Foundation Of State University Of New York Methode de prevention des lesions pulmonaires aiguës
WO2001062261A1 (fr) * 2000-02-25 2001-08-30 Arakis Ltd. Inhibiteurs de metalloproteinase utilises dans le traitement des maladies respiratoires
WO2002072031A2 (fr) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitue utilises en tant qu'antifongiques synergiques
WO2002072022A2 (fr) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues, en tant qu'agents antifongiques
WO2003061767A1 (fr) * 2002-01-25 2003-07-31 Atopic Pty Ltd Techniques et compositions destines au traitement de l'asthme et de troubles associes

Cited By (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001918B2 (en) * 2001-03-13 2006-02-21 Paratek Pharmaceuticals, Inc. 7-pyrrolyl tetracycline compounds and methods of use thereof
US7825105B2 (en) 2002-07-12 2010-11-02 Paratek Pharmaceuticals, Inc. 3, 10, and 12a substituted tetracycline compounds
EP1534300A2 (fr) * 2002-07-12 2005-06-01 Paratek Pharmaceuticals, Inc. Composes de tetracycline substituee en 3, 10, et 12a
US8481513B2 (en) 2002-07-12 2013-07-09 Paratek Pharmaceuticals, Inc. 3, 10, and 12a substituted tetracycline compounds
EP1534300A4 (fr) * 2002-07-12 2008-04-23 Paratek Pharm Innc Composes de tetracycline substituee en 3, 10, et 12a
JP2007520482A (ja) * 2004-01-15 2007-07-26 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物の芳香族ａ環誘導体
EP2332904A3 (fr) * 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derives des composes de tetracycline
US10669244B2 (en) 2004-05-21 2020-06-02 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
JP2011162566A (ja) * 2004-05-21 2011-08-25 President & Fellows Of Harvard College テトラサイクリンおよびそれらの類似物の合成
US11192866B2 (en) 2004-05-21 2021-12-07 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
JP2008500391A (ja) * 2004-05-21 2008-01-10 ザ プレジデント アンド フェローズ オブ ハーバード カレッジ テトラサイクリンおよびそれらの類似物の合成
US9365493B2 (en) 2004-05-21 2016-06-14 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
JP2017052797A (ja) * 2004-05-21 2017-03-16 プレジデント アンド フェローズ オブ ハーバード カレッジ テトラサイクリンおよびそれらの類似物の合成
JP2015221832A (ja) * 2004-05-21 2015-12-10 プレジデント アンド フェローズ オブ ハーバード カレッジ テトラサイクリンおよびそれらの類似物の合成
US9884830B2 (en) 2004-05-21 2018-02-06 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
US8598148B2 (en) 2004-05-21 2013-12-03 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP1778252A4 (fr) * 2004-08-11 2010-01-27 Williamsburg Holdings Llc Composes pharmaceutiques non cardiotoxiques
EP1778252A2 (fr) * 2004-08-11 2007-05-02 Donald L. Barbeau Composes pharmaceutiques non cardiotoxiques
EP2949644A3 (fr) * 2004-10-25 2016-04-20 Paratek Pharmaceuticals, Inc. Composés de tétracycline substituée
EP2284153A3 (fr) * 2004-10-25 2012-03-14 Paratek Pharmaceuticals, Inc. Composés de tétracycline substitués
EP2295419A3 (fr) * 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Composés de tetracyclin substitués
EP2287140A3 (fr) * 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Composés de tétracycline substitués
JP2012111770A (ja) * 2004-10-25 2012-06-14 Paratek Pharmaceuticals Inc 置換テトラサイクリン化合物
US7858601B2 (en) 2004-10-25 2010-12-28 Paratek Pharmaceuticals, Inc. 4-substituted tetracyclines and methods of use thereof
AU2005299569B2 (en) * 2004-10-25 2012-06-07 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP2008518035A (ja) * 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド 置換テトラサイクリン化合物
US8466132B2 (en) 2004-10-25 2013-06-18 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2006047756A2 (fr) * 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues
WO2006047671A2 (fr) * 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines et procedes d'utilisation
WO2006047756A3 (fr) * 2004-10-25 2006-07-20 Paratek Pharm Innc Composes de tetracycline substitues
WO2006047671A3 (fr) * 2004-10-25 2006-08-10 Paratek Pharm Innc 4-aminotetracyclines et procedes d'utilisation
JP2008530106A (ja) * 2005-02-15 2008-08-07 ワイス ９−置換テトラサイクリン
WO2007014154A2 (fr) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. Tetracyclines 10-substituees et leurs procedes d'utilisation
WO2007014154A3 (fr) * 2005-07-21 2007-08-23 Paratek Pharm Innc Tetracyclines 10-substituees et leurs procedes d'utilisation
AU2006272698B2 (en) * 2005-07-21 2012-11-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
JP2009502809A (ja) * 2005-07-21 2009-01-29 パラテック ファーマシューティカルズ インコーポレイテッド １０−置換テトラサイクリンおよびその使用方法
US8101590B2 (en) * 2005-08-31 2012-01-24 Wyeth Llc 9-aminocarbonylsubstituted derivatives of glycylcyclines
JP2009507793A (ja) * 2005-08-31 2009-02-26 ワイス グリシルサイクリンの９−アミノカルボニル置換誘導体
JP2009522380A (ja) * 2006-01-10 2009-06-11 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッド 抗腫瘍活性を有するタキソール誘導体
US8486921B2 (en) 2006-04-07 2013-07-16 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
US8293920B2 (en) 2006-10-11 2012-10-23 President And Fellows Of Harvard College Synthesis of enone intermediate
US8907104B2 (en) 2006-10-11 2014-12-09 President And Fellows Of Harvard College Synthesis of enone intermediate
US8580969B2 (en) 2006-10-11 2013-11-12 President And Fellows Of Harvard College Synthesis of enone intermediate
WO2008079363A3 (fr) * 2006-12-21 2008-10-02 Paratek Pharm Innc Utilisation de composés à base de tétracycline substituée dans le traitement d'affections cutanées inflammatoires
JP2015205939A (ja) * 2006-12-21 2015-11-19 パラテック ファーマシューティカルズ インコーポレイテッド 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
EP2455367A1 (fr) * 2006-12-21 2012-05-23 Paratek Pharmaceuticals, Inc. Dérivés de tétracycline pour le traitement d'infections bactériennes, virales et parasites
US9481639B2 (en) 2006-12-21 2016-11-01 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
US9012433B2 (en) 2006-12-21 2015-04-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
EP2450347A1 (fr) * 2006-12-21 2012-05-09 Paratek Pharmaceuticals, Inc. Dérivés de tétracycline pour le traitement d'infections bactériennes, virales et parasites
JP2021063137A (ja) * 2006-12-21 2021-04-22 パラテック ファーマシューティカルズ，インコーポレイテッド 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
JP2011093914A (ja) * 2006-12-21 2011-05-12 Paratek Pharmaceuticals Inc 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
JP2010513527A (ja) * 2006-12-21 2010-04-30 パラテック ファーマシューティカルズ インコーポレイテッド 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
JP2018039846A (ja) * 2006-12-21 2018-03-15 パラテック ファーマシューティカルズ インコーポレイテッド 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
US8513223B2 (en) 2006-12-21 2013-08-20 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
KR101538175B1 (ko) * 2006-12-21 2015-07-20 파라테크 파마슈티컬스, 인크. 박테리아, 바이러스 및 기생충 감염의 치료를 위한 테트라시클린 유도체
AU2007338681B2 (en) * 2006-12-21 2013-09-26 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
US8318706B2 (en) 2006-12-21 2012-11-27 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP2014167027A (ja) * 2006-12-21 2014-09-11 Paratek Pharmaceuticals Inc 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
WO2008079363A2 (fr) * 2006-12-21 2008-07-03 Paratek Pharmaceuticals, Inc. Utilisation de composés à base de tétracycline substituée dans le traitement d'affections cutanées inflammatoires
EP3488853A1 (fr) * 2006-12-21 2019-05-29 Paratek Pharmaceuticals, Inc. Composés de tétracycline substituée pour le traitement de troubles inflammatoires de la peau
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
US8513219B2 (en) 2007-05-02 2013-08-20 Queen Mary & Westfield College, University Of London Substituted phosphonates and their use in decreasing amyloid aggregates
JP2014221820A (ja) * 2008-03-28 2014-11-27 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物の経口製剤および注射可能な製剤
JP2018203778A (ja) * 2008-03-28 2018-12-27 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物の経口製剤および注射可能な製剤
EP2307027A1 (fr) * 2008-07-11 2011-04-13 Neumedics Dérivés de tétracycline présentant une activité antibiotique réduite et des bénéfices neuroprotecteurs
EP2307027A4 (fr) * 2008-07-11 2012-08-15 Neumedics Dérivés de tétracycline présentant une activité antibiotique réduite et des bénéfices neuroprotecteurs
US8338477B2 (en) 2008-07-11 2012-12-25 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
US9168265B2 (en) 2008-07-11 2015-10-27 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
US9573912B2 (en) 2008-07-11 2017-02-21 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
US9896422B2 (en) 2008-07-11 2018-02-20 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
EP2341771A4 (fr) * 2008-09-19 2012-08-15 Paratek Pharm Innc Composés de tétracycline utilisés dans le traitement de la polyarthrite rhumatoïde et méthodes thérapeutiques associées
JP2012503017A (ja) * 2008-09-19 2012-02-02 パラテック ファーマシューティカルズ インコーポレイテッド 関節リウマチの治療用のテトラサイクリン化合物および関連する治療方法
EP2341771A1 (fr) * 2008-09-19 2011-07-13 Paratek Pharmaceuticals, Inc. Composés de tétracycline utilisés dans le traitement de la polyarthrite rhumatoïde et méthodes thérapeutiques associées
US9688644B2 (en) 2009-04-30 2017-06-27 President And Fellows Of Harvard College Synthesis of Tetracyclines and intermediates thereto
US9073829B2 (en) 2009-04-30 2015-07-07 President And Fellows Of Harvard College Synthesis of tetracyclines and intermediates thereto
EP2544692A4 (fr) * 2010-03-10 2013-08-07 Univ Health Network Utilisation de la tigécycline pour le traitement du cancer
CN102821769A (zh) * 2010-03-10 2012-12-12 大学健康网络 替加环素用于治疗癌症的用途
EP2544692A1 (fr) * 2010-03-10 2013-01-16 University Health Network Utilisation de la tigécycline pour le traitement du cancer
CN102204921A (zh) * 2011-04-14 2011-10-05 苏州大学 一种四环素类衍生物在制备放疗增敏药物中的应用
CN103717571A (zh) * 2011-07-26 2014-04-09 山东亨利医药科技有限责任公司 9-氨基甲基取代的四环素类化合物
WO2013013505A1 (fr) 2011-07-26 2013-01-31 山东亨利医药科技有限责任公司 Composé tétracycline substitué par 9-aminométhyle
CN103717571B8 (zh) * 2011-07-26 2017-05-17 山东亨利医药科技有限责任公司 9‑氨基甲基取代的四环素类化合物
US9365499B2 (en) 2011-07-26 2016-06-14 Kbp Biosciences Co., Ltd. 9-aminomethyl substituted tetracycline compounds
EP2738156A4 (fr) * 2011-07-26 2015-01-07 Kbp Biosciences Co Ltd Composé tétracycline substitué par 9-aminométhyle
EP2738156A1 (fr) * 2011-07-26 2014-06-04 KBP Biosciences Co., Ltd. Composé tétracycline substitué par 9-aminométhyle
US9518011B2 (en) 2012-11-21 2016-12-13 Nippon Soda Co., Ltd. Recording material produced using non-phenol compound
CN103142624A (zh) * 2013-03-01 2013-06-12 西南大学 抗生素替加环素在制备抗癌药物中的应用
US11400156B2 (en) 2015-02-09 2022-08-02 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections
US10610588B2 (en) 2015-02-09 2020-04-07 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections
EP3256135A4 (fr) * 2015-02-09 2018-06-27 Yeda Research and Development Co. Ltd. Procédés pour prévenir des infections secondaires
CN109563035B (zh) * 2016-06-22 2021-07-20 山东亨利医药科技有限责任公司 9-氨基甲基取代的四环素类化合物的晶型及其制备方法
CN109563035A (zh) * 2016-06-22 2019-04-02 山东亨利医药科技有限责任公司 9-氨基甲基取代的四环素类化合物的晶型及其制备方法
WO2019241466A1 (fr) 2018-06-13 2019-12-19 Texas Tech University System Tétracycline modifiée pour le traitement des troubles de l'usage de l'alcool, de la douleur et d'autres troubles impliquant des processus inflammatoires potentiels
EP3806865A4 (fr) * 2018-06-13 2022-06-01 Texas Tech University System Tétracycline modifiée pour le traitement des troubles de l'usage de l'alcool, de la douleur et d'autres troubles impliquant des processus inflammatoires potentiels
US11542227B2 (en) 2018-06-13 2023-01-03 Texas Tech University System Modified tetracycline for treatment of alcohol use disorder, pain and other disorders involving potential inflammatory processes
WO2022079204A1 (fr) 2020-10-14 2022-04-21 Institut Du Cerveau Et De La Moelle Epiniere Dérivés de tétracycline pour le traitement de maladies neurodégénératives ou neuroinflammatoires
WO2022167954A1 (fr) * 2021-02-03 2022-08-11 Skybio Llc Transporteur chimiquement couplé pour médicaments bioactifs à faible hydrophobicité dans le système nerveux central
US11951170B2 (en) 2021-02-03 2024-04-09 Skybio Llc Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system
WO2024008951A1 (fr) 2022-07-08 2024-01-11 Icm (Institut Du Cerveau Et De La Moelle Épinière) Dérivés de tétracycline

Also Published As

Publication number Publication date
WO2004064728A3 (fr) 2004-12-16

Similar Documents

Publication Publication Date Title
EP1408987B1 (fr) Composes de tetracycline a activites therapeutiques cibles
US20180016225A1 (en) Tetracycline compounds having target therapeutic activities
WO2004064728A2 (fr) Composes de tetracycline possedant des activites therapeutiques ciblees
DK2120963T3 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS
EP2109602B1 (fr) Derivés de la tetracycline pour le traitement de infections bacterielles, virales et parasitiques
US8088755B2 (en) 11a, 12-derivatives of tetracycline compounds
CA2721399A1 (fr) Composes a base de tetracyclines substituees
AU2012207049A1 (en) 11a, 12-derivatives of tetracycline compounds
AU2013231126A1 (en) Substituted tetracycline compounds for the treatment of inflammatory skin disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase